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Abstract 
Non-typeable Haemophilus influenzae (NTHi) are Gram-negative bacteria that reside in the 
upper respiratory tract of humans. As well as being part of the normal flora, they are 
opportunistic pathogens, causative of non-invasive respiratory tract infections, and an 
occasional cause of invasive infections. In the Australian aboriginal population, a high 
prevalence of otitis media (OM) in children is a factor that contributes significantly to their 
educational and economic disadvantage, and NTHi is the most important cause of recurrent 
OM cases. In the worldwide adult population, NTHi causes approximately 25% of the 
“exacerbations” of chronic obstructive pulmonary disease (COPD), which ultimately lead to 
death in most cases. NTHi is transmitted by respiratory secretions, initially colonising the 
pharynx, and in the case of disease, moves to the lower respiratory tract (COPD) or middle ear 
(OM). Efforts to treat and prevent NTHi infection have been hampered by antibiotic resistance 
and difficulty in finding suitable vaccine targets, and alternative treatment or prevention 
strategies are therefore desired. Bacterial therapy (probiotics) for the prevention of respiratory 
tract infections, based on co-colonizing bacteria, has been a topic of research in the 21st century, 
and a commercial preparation of Streptococcus salivarius (BLIS K12TM) is now available for 
the prevention of S. pyogenes infections, and another S. salivarius preparation (24SMB) is 
patented for prevention of S. pneumoniae infections. However, there have so far been no co-
colonizing probiotics developed specifically for the prevention of NTHi infections. 
Haemophilus haemolyticus are bacteria that are closely related to NTHi, also colonize the upper 
respiratory tract of humans, but are not opportunistic pathogens of the respiratory tract, and 
only very rarely causative of invasive infections in the immunocompromised host. Recently, 
pre-treatment of epithelial cells with H. haemolyticus was shown to prevent NTHi attachment, 
and as a result, H. haemolyticus was suggested as a possible agent of bacterial therapy 
(Pickering et al., 2016). 
x 
In this project, the NTHi-inhibitory activity of H. haemolyticus was investigated, with a focus 
on secreted substances.  Initially, SYBR Green real-time (RTPCR) assays were developed for 
the identification of the two species, which were then applied to a collection of isolates from 
Australian pathology laboratories. The H. haemolyticus isolates were then screened for 
inhibition of NTHi, using co-culture and agar well diffusion assays. Two H. haemolyticus 
isolates (BW1 and RHH122) were identified as consistent producers of an NTHi inhibitory 
substance (NIS), and the physical and chemical properties of the NIS produced by BW1 were 
characterised and published. The NIS produced by BW1 (BW1-NIS) and RHH122 (RHH122-
NIS) were identified, by mass spectrometry analysis and comparison with published whole 
genome sequences, as identical to a putative 27 kDa OMPA-like protein in H. haemolyticus 
isolate M19107. A recombinant version of this H. haemolyticus NIS (Hh-NIS), made in E. coli 
from the Hh-NIS ORF without signal peptide, also inhibited NTHi. With in silico structural 
modelling, similarities were identified between Hh-NIS and the haemoglobin-haptoglobin 
utilisation protein A (hpuA) in Kingella denitrificans and Neisseria gonohorreae. The 
spectrum of absorbance of Hh-NIS identified haem as a likely component, and with cation 
exchange chromatography, Hh-NIS was separated into a holoprotein fraction, containing haem 
as a ligand, and an apoprotein fraction, from which haem was absent. As the activity of both 
fractions against NTHi was similar, and the addition of haemin neutralised the activity of Hh-
NIS, haem was considered not to be a co-factor required for activation of an enzyme, but that 
it had another role. The addition of purified Hh-NIS holoprotein to broth cultures, resulted in 
inhibition of NTHi growth, and promotion of growth of an Hh-NIS producing strain of H. 
haemolyticus (BW1), but only in haemin-limited conditions. A model mechanism for activity 
was described, whereby Hh-NIS is a haemophore that binds haem, making it available to 
producing strains, but unavailable to NTHi. To further understand the biological function and 
importance of Hh-NIS to H. haemolyticus, construction and testing of a knockout mutant, the 
xi 
 
elucidation of the control of Hh-NIS secretion and utilisation, and in vivo testing in animal 
models are recommended. With regards to its application as a probiotic for NTHi control in 
humans, in the continued absence of an effective vaccine, in vivo testing of H. haemolyticus 
strains which produce Hh-NIS is recommended, although as haem-acquisition genes are 
associated with pathogenicity, a cautionary approach should be taken. 
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1.1 Haemophilus influenzae 
Haemophilus influenzae are Gram-negative, facultatively anaerobic, coccobacillary bacteria, 
with the upper respiratory tract of humans their reservoir. These bacteria are nutritionally 
fastidious, and require nicotinamide adenine dinucleotide (NAD, V factor), along with a source 
of haem (X factor), which may also be provided in the form of haemin, haematin or 
haemoglobin. H. influenzae can be divided into typeable and non-typeable forms depending on 
the presence or absence of a polysaccharide capsule, with the capsulated (typeable) forms 
classified into one of six serotypes (a to f) based on the reactivity of antisera with their capsule 
(Pittman, 1933). 
Although H. influenzae are frequent colonizers of healthy children and adults (Lemon et al., 
2010; Murphy et al., 2009), they are also an important cause of disease. The most clinically 
relevant serotype is H. influenzae type b (Hib), which causes serious invasive infections, 
including meningitis and pneumonia, particularly in children and infants. With the introduction 
in the 1980s of routine immunisation with a polyribosylribitol phosphate (type b capsular 
polysaccharide) vaccine, and then a conjugate version also in the 1980s and beyond, the 
incidence of invasive infection due to this serotype has dramatically decreased, such that the 
risk in developed countries is now almost negligible (Peltola, 2000). Still, the risk of Hib 
infection remains high in non-vaccinated populations, particularly in developing countries 
(Obonyo and Lau, 2006). However, the focus of H. influenzae research has now shifted to the 
non-typeable H. influenzae (NTHi). 
1.2 Non-typeable Haemophilus influenzae (NTHi) 
After the introduction of routine vaccination against Hib, and the polysaccharide conjugate 
vaccine (PCV) against Streptococcus pneumoniae in the early 2000s, the global impact on 
health due to Hib and S. pneumoniae infections was reducing, but the relative and absolute 
Chapter 1. Literature Review 
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impact due to NTHi infections was increasing. The main explanation given for the change, was 
the “strain replacement” of Hib and S. pneumoniae by NTHi (Biesbroek et al., 2014; Langereis 
and de Jonge, 2015; Spijkerman et al., 2012). NTHi and non-vaccine-preventable S. 
pneumoniae are now the leading causes of otitis media in children (Ngo et al., 2016), and 
exacerbations of chronic obstructive pulmonary disease (Rosell et al., 2005; Sethi and Murphy, 
2008). It is now also the case that NTHi have become increasingly important in bacterial 
conjunctivitis, bacterial sinusitis, exacerbations of cystic fibrosis, persistent bacterial 
bronchitis, and pneumonia (Van Eldere et al., 2014). Additionally, NTHi have replaced Hib as 
the leading cause of invasive infections for this species, and there is a particularly high 
incidence in infants, the indigenous and the elderly (Adam et al., 2010; Resman et al., 2011; 
Van Eldere et al., 2014; Wan Sai Cheong et al., 2015; Whittaker et al., 2017). 
1.3 Antimicrobial therapy  
Despite some NTHi infections such as simple otitis media being self-limiting, most NTHi 
infections are managed with antimicrobial therapy. The most commonly used agents are β-
lactams, including aminopenicillins alone or in combination with a β-lactamase inhibitor, and 
cephalosporins  (Tristram et al., 2007). Although most macrolides have relatively low activity 
against NTHi (Jacobs et al., 2003), the newer and more active derivatives, such as 
azithromycin, have occasional application due to their broad spectrum activity against 
respiratory pathogens, as well as their immunomodulatory and anti-inflammatory effects 
(Kovaleva et al., 2011; Sriram et al., 2017) Although most NTHi infections can be managed 
with antimicrobials, resistance is an increasing problem. 
1.4 Antimicrobial resistance 
Resistance to β-lactams is widespread in NTHi, and may be chromosomally or plasmid 
encoded. In NTHi, high-level resistance to aminopenicillins is conferred by plasmid encoded 
  Chapter 1. Literature Review 
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TEM-1 and ROB-1 β-lactamases. Although the prevalence of this type of resistance is quite 
variable, in most regions it is 20-30% (Farrell et al., 2005; Gilsdorf, 2015; Tristram et al., 2007). 
Of concern is the increasing prevalence of NTHi strains with a chromosomally encoded altered 
penicillin binding protein 3 (Dabernat and Delmas, 2012). These strains, referred to as β-
lactamase negative ampicillin resistant (BLNAR), have decreased susceptibility to all β-
lactams, and their prevalence in most parts of the world is around 20%, but is more than 50% 
in some areas including Japan (Wajima et al., 2016). Although this resistance was initially 
considered to have arisen only from de novo mutations, it is has been shown to be transferable 
between strains via transformation and recombination, (Søndergaard et al., 2015; Takahata et 
al., 2007; Witherden et al., 2014) which may account for the rapid rise in prevalence. 
Resistance to macrolides is common in NTHi, yet they are still in use. Although most NTHi 
have an AcRAB type efflux pump (Sanchez et al., 1997), which results in low-level resistance 
to macrolides (Pettigrew et al., 2016), they are still usually susceptible at clinically relevant 
concentrations (Cameron et al., 2012; Sriram et al., 2017; Tristram et al., 2007). The existence 
of high-level resistance, conveyed by  transferable acquired macrolide resistance genes of the 
erm and mef types, has been demonstrated in NTHi (Roberts et al., 2010), but its importance 
is disputed (Atkinson et al., 2015; Pettigrew et al., 2016; Seyama et al., 2016). However, the 
value of macrolide therapy would likely be greatly diminished if these genes do become 
established in NTHi, as they have done in Gram-positive bacteria.  
The reliability of antimicrobial therapy for treatment of NTHi infections is clearly being 
diminished by an increase in the spectrum and prevalence of resistance, and combined with its 
increasing importance as a pathogen, has resulted in NTHi being entered onto a “priority 
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pathogens list” by the World Health Organisations, for guidance into research, discovery and 
development of new antibiotics (World Health Organisation, 2017).  
1.5 Vaccines 
Despite being a topic of research for more than three decades, there is still no effective vaccine 
for protection against NTHi infection. Inactivated whole-cell NTHi oral vaccines have been 
tested extensively (Sriram et al., 2017), but their efficacy has been only moderate or 
insignificant (Clancy et al., 2016; Teo et al., 2017).  
More recent efforts have focused on the use of specific antigens, and a list of those under study 
has been compiled (Khan et al., 2016; Murphy, 2015). Confounding factors in the use of these 
antigens for vaccine development have been the absence of a capsular target, phase variability 
(Atack et al., 2015; Fox et al., 2014; VanWagoner et al., 2016) and the extreme heterogeneity 
of NTHi isolates (Eutsey et al., 2013), and as yet, no single antigen has been discovered that is 
characteristic of all pathogenic strains (Cerquetti and Giufrè, 2016). However, protein D (hpd) 
has been incorporated as a carrier into the currently available pneumococcal conjugate vaccine 
(PHiD-CV), and some efficacy against NTHi carriage and disease rates has been demonstrated. 
In a randomised double-blind pneumococcal otitis efficacy trial (POET), 11Pn-PD, the 
prototype vaccine for PHiD-CV, reduced the number of cases of acute OM caused by NTHi 
(Prymula et al., 2006), as well as the carriage rate (Prymula et al., 2009). Then, in Australian 
aboriginal communities, PHiD-CV in place of 7-valent PCV was associated with a reduction 
in suppurative OM (Leach et al., 2014), which was then linked to a reduction in NTHi in the 
ear discharge (Leach et al., 2015). Later, in the same communities, with the transition from 
PHiD-CV to a 13-valent PCV (without hpd), the presence of NTHi in the OM ear discharge 
was increased (Leach et al., 2016). However, a concern with the use of hpd as the only NTHi 
antigen in a vaccine , is the existence of a subset of disease-associated true NTHi strains that 
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are clearly deficient in hpd (Smith-Vaughan et al., 2014), and while none of the strains were 
from PHiD-CV vaccinated individuals, a concern remains that continued use of the vaccines 
would positively select for these organisms. Were such an increase in the prevalence of hpd-
deficient NTHi to occur, any efficacy of the vaccines against NTHi would likely be reduced. 
However these concerns may be an overstatement, as a different study has shown that hpd-
deficient NTHi mutants were approximately 100-fold less virulent (Janson et al., 1994). 
Although researchers are hopeful that a vaccine with substantial efficacy will be developed in 
the next decade (Khan et al., 2016; Murphy, 2015), there is no certainty that it will happen, and 
the development of a non-antibiotic, non-vaccine approach to controlling NTHi infection 
should be considered.  
1.6 Microbial interference 
The deliberate introduction of commensal bacteria that are antagonistic to pathogens, is an 
approach that has had extensive research, as well as discussion in the medical and wider 
communities. This “microbial interference” approach, or “probiotics” as it is more commonly 
known, is normally associated with the ingestion of live lactic acid bacteria, for their beneficial 
effects, perceived or otherwise, in the gastrointestinal tract, or the immune system in general. 
However, in parallel to this research, there exists a substantial although smaller body of 
research, concerning the use of microbial interference for the prevention or treatment of 
infections in the upper respiratory tract. Reviews of this topic (Brook, 2005; Esposito et al., 
2014; Hao et al., 2015; Marom et al., 2016; Popova et al., 2012; Vouloumanou et al., 2009) 
show the undoubtable focus of this research has been on the the prevention or treatment of S. 
pyogenes and S. pneumoniae infections, or the non-specific immune-modulatory effects of 
Lactobacillus spp. and  Bifidobacterium  spp.. Although the results are variable, as shown 
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below, there are a sufficient number of examples of treatment efficacy for this approach to be 
taken seriously.  
A strain of Streptococcus salivarius from the throat of a healthy child (Smith et al., 1993), has 
been developed into the commercially available, orally administered preparation, BLIS K12tm.  
This strain produces the bacteriocins, salivaricin A2 and salivaricin B (Hyink et al., 2007), with 
activity against S. pyogenes. The effectiveness of BLIS K12tm for prevention of a range of 
conditions has been reviewed, with results suggestive of efficacy against respiratory tract 
infections (Zupancic et al., 2017).  In all of four small clinical trials (Di Pierro et al., 2012, 
2013, 2014; Gregori et al., 2016), BLIS K12tm was protective against pharyngitis and/ or 
tonsillitis. Also, in small trials of BLIS K12tm for protection against acute otitis media, although 
less convincing, protective activity was observed (Di Pierro et al., 2015; Power et al., 2008; 
Walls et al., 2003). 
An isolate of S. oralis (89a, previously S. sanguinis 89a), taken from a healthy child during an 
outbreak of S. pyogenes tonsillitis in Sweden, was shown to have in vitro activity against S. 
pyogenes (Grahn and Holm, 1983). Then, in a double-blinded placebo controlled trial on 
children with chronic secretory OM, 7 of 19 treated with an S. oralis 89a nasal spray were 
cured or much improved, compared with 1 of 17 in the placebo group (Skovbjerg et al., 2009), 
a significant difference (p=0.044). 
A strain of S. salivarius (24SMB) with activity against S. pneumoniae has been patented for 
treatment of chronic  respiratory tract infections (U.S. Patent No. 20130095044 A1, 2013). 
When tested in vitro, this strain produced a BLIS which inhibited S. pneumoniae, (Santagati et 
al., 2012), and, in a small clinical trial, nasally administered 24SMB colonized the nasopharynx 
and reduced the rates of paediatric otitis media (Marchisio et al., 2015), although the 
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differences were insignificant, and conclusions disputed (Di Mario et al., 2016; Marchisio et 
al., 2016). 
Recently, and more convincingly, a retrospective observational study was performed on 
children with recurrent acute OM, with the treatment consisted of a nasal spray containing S. 
salivarius 24SMB and S. oralis 89a (La Mantia et al., 2017). There were 108 participants in 
the control group and 159 in the treatment group. In the treatment group, there was a significant 
reduction (p<0.0001) in both the number of episodes and severity index of OM. 
In an example of a preliminary study, with results that may lead to the development of 
probiotics for the respiratory tract, S. aureus inhibitory activity was examined in a collection 
of intra-nasal Staphylococcus spp. The S. lugdunensis isolate IVK28 produced lugdunin, a 
novel antibiotic with activity against Gram-positive pathogens, including S. aureus (Zipperer 
et al., 2016). To further investigate this, intra-nasal colonisation by S. aureus and S. lugdunensis 
was studied in specimens from 187 hospitalised patients.  The results showed that carriage of 
S. lugdunensis was associated with a 5.9-fold reduction in S. aureus carriage, and that all S. 
lugdunensis isolates were positive for the lug operon, and all S. aureus were sensitive for 
lugdunin.  
Finally, in one of the few examples of studies on Gram-negative bacteria, intra-nasal 
inoculation of Neisseria lactamica reduced the carriage of N. meningitidis.  Following on from 
studies showing carriage and disease of N. meningitidis and N. lactamica  were inversely 
related (Cartwright et al., 1987; Gold et al., 1978; Olsen et al., 1991), an N. lactamica strain 
(Y92–1009), which had been used for manufacture of an outer membrane vesicle-based 
vaccine against N. meningitidis (Gorringe et al., 2009), was administered intra-nasally to young 
adults. The individuals treated with the N. lactamica experienced an increased rate of 
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displacement of N. meningitidis, as well as a reduced rate of N. meningitidis acquisition (Deasy 
et al., 2015). 
As NTHi colonisation of the upper airways is required prior to the development of respiratory 
tract infections (King, 2012), the inhibition of colonisation is an appealing target for prevention 
of infection. In the absence of a suitable vaccine, this may be achieved through microbial 
interference. However, we are unaware of any research on the development of a probiotic 
directed against NTHi colonisation, but we suggest that H. haemolyticus is an agent that should 
be considered.  
1.7 Haemophilus haemolyticus 
Criteria for a successful probiotic strain include occupation of the same niche as the pathogen, 
absence of pathogenicity, and inhibition of the pathogen (Dunne et al., 2001). Interestingly, for 
development of a probiotic against NTHi, Hib strains partially fulfil these criteria in that they 
occupy the same niche and secrete the bacteriocin “haemocin”, which has activity against 
NTHi (LiPuma et al., 1990, 1992; Venezia and Robertson, 1975). However, Hib would be 
inappropriate as a probiotic, as they have the potential to cause serious disease in non-
vaccinated individuals, and would not establish in the upper respiratory tract of those that have 
been vaccinated.  
H. haemolyticus, like H. influenzae, are bacteria that are resident of the upper respiratory tract 
of healthy adults and children. The two species are genetically and phenotypically closely 
related, with both dependent on X and V growth factors. However, unlike H. influenzae, H. 
haemolyticus is not considered to be an opportunistic pathogen, and although H. haemolyticus 
may be frequently isolated from the respiratory tract of COPD patients, the acquisition of new 
strains was not associated with exacerbations (Murphy et al., 2007).  Nevertheless, H. 
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haemolyticus is a rare cause of invasive disease in the immunocompromised. The species was 
first described in 1919 (Pritchett and Stillman, 1919), and apart from two cases of endocarditis 
reported shortly there afterwards (De Santo and White, 1933; Miller and Branch, 1923), the 
next reported cases of H. haemolyticus causing disease were in 2011, with five patients 
identified with invasive disease, but with no other details given (Jordan et al., 2011). In 2012 
there were six reported cases of bacteraemia due to H. haemolyticus,  along with a single case 
each of peritonitis and septic arthritis (Anderson et al., 2012; Morton et al., 2012). These 13 
cases from 2011 and 2012 were identified from collections of invasive disease causing isolates, 
which had been initially identified as H. influenzae, and their identities had been later re-
examined using molecular methods. 
Differentiation of H. haemolyticus from H. influenzae has always been problematic, as it 
inhabits the same niche, and has much the same phenotypic characteristics. The main 
characteristic used for differentiating the two organisms has been beta-haemolysis, which is 
unreliable. In a landmark prospective study of apparent NTHi obtained from various clinical 
sources in COPD patients, the 12 H. haemolyticus isolated from throat swabs were all non-
haemolytic, and 50 of 102 isolates of H. haemolyticus from sputum were also non-haemolytic 
(Murphy et al., 2007). To address this problem in H. haemolyticus identification, molecular 
methods have been developed, and are reviewed in the introduction to Chapter 4 of this thesis.  
Although H. haemolyticus has been described as an emerging pathogen (Jordan et al., 2011), 
its mechanisms of pathogenicity are poorly understood (Anderson et al., 2012). Typically 
invasive pathogens (Hib, S. aureus, S. pyogenes, and N. meningitidis) have a capsule, but there 
are no reports of capsule formation by H. haemolyticus, which is also the case for NTHi. The 
haemolytic characteristic of the organism is the due to the production of a hemolysin, 
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substances which in S. aureus and S. pyogenes are virulence factors, but in H. haemolyticus the 
biological role of hemolysin production is unknown (Anderson et al., 2012). Phase-variable 
phosphoryl choline (ChoP) modification of lipooligosaccharide, is a virulence factor of NTHi 
for evasion and attachment (Hong et al., 2007; Weiser et al., 1997), encoded by the lic1 locus. 
In a study of lic1 in these two organisms, it was present in 92% of NTHi, and also 43% of H. 
haemolyticus (McCrea et al., 2010a).  However, in H. haemolyticus, the encoded ChoP was 
less diverse, which was suggested to be related to reduced virulence.  In an in vitro investigation 
of the interaction of host cells with H. haemolyticus and NTHi (Pickering et al., 2016), there 
were clear differences. Although H. haemolyticus was less able to attach to and 
invade nasopharyngeal and bronchoalveolar epithelial cells, exposure to H. haemolyticus also 
resulted in increased cytotoxicity and an inflammatory (IL-6 and IL-8) response, but exposure 
to NTHi did not. Clearly, despite the similarities of the two organisms, there are differences in 
how they interact with the host. 
The organisms H. haemolyticus and H. influenzae, both colonize the same locations of the 
upper respiratory tract, but there is substantial variability between individuals. In a collection 
of isolates originating from regular monthly morning collection of spontaneously expectorated 
sputum of COPD patients (Sethi et al., 2002), the NTHi isolates, which had been identified 
with conventional methods, were re-identified with molecular methods, and 102 of 258 (40%) 
were H. haemolyticus, with the balance H. influenzae (Murphy et al., 2007). Also, when the 
authors re-examined with molecular methods, the 44 NTHi isolates from throat swabs of 
healthy children in day-care, which had been originally identified by conventional methods 
which did not differentiate H. haemolyticus (Farjo et al., 2004), 12 (27%) were found to be H. 
haemolyticus, and 32 (73%) NTHi. In the same study, Murphy and colleagues provided 
evidence that H. haemolyticus is not a cause of opportunistic respiratory tract infections, when, 
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in their re-identification of 130 NTHi isolates from middle ear fluids of acute otitis media 
patients by molecular methods, all were identified as NTHi. Additional retrospective studies of 
apparent NTHi respiratory isolates have similarly found no evidence that H. haemolyticus is a 
respiratory pathogen, with  only 2 out of 480 isolates (Norskov-Lauritsen, 2009),  and 7 out of 
447 isolates (Zhang et al., 2014), identified as H. haemolyticus, and in neither study were the 
H. haemolyticus shown to be of clinical significance.  
In a study of H. influenzae and H. haemolyticus pharyngeal colonisation dynamics, regular 
throat swabs were taken from four healthy adults over a seven month period, and isolates of 
both species were identified with molecular methods (Mukundan et al., 2007). Over the whole 
study, 16% of the isolates were H. haemolyticus, and 84% were NTHi, however, between the 
adults there was extreme variability.  From adult B, 236 of 237 (99.6%) isolates were NTHi, 
and adult D, 48 of 48 (100%) isolates were H. haemolyticus, with the results for adults A and 
C between these two extremes.  
As shown above, when H. haemolyticus and NTHi are co-inhabitants of the upper respiratory 
tract, they can do so with the apparent absence of bacterial infection at that particular site. 
Conceivably, when these bacteria are co-located, due to their common growth requirements, 
H. haemolyticus are controlling the out-growth of NTHi. Such activity would suggest 
antagonism of NTHi growth by H. haemolyticus, and  supports a previously described idea, 
that H. haemolyticus may be useful as a bacterial therapy (probiotic) against NTHi infection 
because it may block colonization (Pickering et al., 2016). The idea had evolved from results 
in their study, which showed that pre-treatment with H. haemolyticus reduced the number of 
NTHi which could attach to epithelial cells in vitro. However the underlying mechanisms for 
the inhibition of attachment were not investigated.  
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With the purpose of developing strains of H. haemolyticus as probiotics, to supplement 
antibiotics for the control of NTHi, prior to development of an effective vaccine, we now seek 
to uncover any inhibitory activity of H. haemolyticus toward NTHi, with a focus on secreted 
substances. 
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2.1 Bacterial collection 
The H. haemolyticus and NTHi isolates in this study originated from respiratory tract 
specimens, and were kindly provided by hospital laboratories around Australia. As they were 
obtained from routine procedures, ethics approval was not required.  The isolates were initially 
identified by colony morphology, Gram-stain, X and V factor dependency, and haemolysis 
testing, and were subsequently identified by 16S sequencing and RTPCR for species specific 
markers (Latham et al., 2015). 
Twenty Hib isolates, MDU 1 through to MDU 20, were kindly provided by Dr Ben Howden 
of the Medical Diagnostic Unit of the Doherty Institute for Infection and Immunity, Melbourne, 
VIC, Australia. Their origins and methods for identification were not disclosed. 
The Haemophilus reference strains used in our study consisted of eight H. influenzae (ATCC 
9007, ATCC 43163, ATCC 10211, ATCC 49766, NCTC 8468, NCTC 4560, NCTC 11315, 
86-028 NP) and one H. haemolyticus strain, ATCC 33390.  
Bacterial strains other than Haemophilus, as used for sensitivity testing, were kindly provided 
by Mr David Jones, senior microbiologist, Royal Hobart Hospital, TAS, Australia. 
2.2 Culture Media 
2.2.1 Chocolate agar (CA) 
Chocolate agar (CA) was used for revival, subculturing, and enumeration of Haemophilus spp. 
Plates of CA were prepared by autoclaving a mixture of 19.5g of Columbia blood agar base 
(Oxoid, CM0331) with 500mL of distilled water at 121°C for 30 minutes, immersion in an 
80°C water bath for 30 minutes, mixing in 25mL of defibrinated horse blood (Oxoid, HB250) 
by swirling for 2 minutes, transferring to a 50°C water bath for 30 minutes, then mixing in half 
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a vial of resuspended Vitox supplement (Oxoid SR0090A), and pouring 10-15mL in 90mm 
polystyrene Petri dishes. 
2.2.2 Supplemented brain heart infusion broth (sBHIB) 
Brain heart infusion (Oxoid, CM1135) was dissolved in distilled water at the rate specified by 
the manufacturer, autoclaved at 121°C for 30 minutes, cooled to 50°C, then supplemented with 
HTM supplement (Oxoid, SR0158) and Vitox (Oxoid SR0090A) at the rate recommended by 
the manufacturer. 
2.2.3 Half-strength supplemented brain heart infusion agar (0.5xsBHIA) 
For the preparation of half strength supplemented brain heart infusion agar (0.5xsBHIA), half 
the manufacturer rate of brain heart infusion (Oxoid, CM1135) was mixed with 7.5g/L 
bacteriological agarose (Oxoid, LP0011), autoclaved at 121°C for 30 minutes, cooled to 50°C, 
then supplemented with half the manufacturer recommended rates of HTM supplement (Oxoid, 
SR0158) and Vitox (Oxoid, SR0090A). 
2.2.4 Supplemented tryptone soya broth (sTSB) 
Cold Filterable Tryptone Soya Broth (Oxoid, CM 1065) was dissolved in distilled water at the 
manufacturer specified rate, then sterilised by 0.2µm membrane filtration, and supplemented 
with HTM supplement (Oxoid, SR0158) and Vitox (Oxoid SR0090A) at the rate recommended 
by the manufacturer, or supplemented with NAD and haemin as specified. 
2.2.5 Haemin solution 
2 mg/mL haemin (Sigma, 51280) was prepared in 0.1M NaOH by mixing for 220 RPM at 37°C 
for 1 hour, then sterilization by filtration through a 0.2µm membrane. Aliquots were frozen at 
-20°C and used on the same day as thawing.  
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2.2.6 Nicotinamide adenine dinucleotide (NAD) solution 
1 mg/mL Nicotinamide adenine dinucleotide (NAD) in water was sterilized by filtering 
through a 0.2µm membrane. Aliquots were frozen at -20°C and used on the same day as 
thawing.  
2.2.7 Skim milk media (SMM) 
Skim milk media (SMM) was used for storage of isolates at -80°C, and consisted of 100g/L 
skim milk powder (Diploma, Australia) dissolved in Dulbecco’s phosphate buffered saline 
(DPBS, Gibco, 14190-250), which was then  autoclaved at 110°C for 15 minutes.  
2.3 Incubation of cultures 
2.3.1 Solidified media in petri dishes 
Incubation was in a humidified atmosphere at 35°C with 5% CO2 for 16-24 hours. 
2.3.2 Agitated Broth  
Incubation was in an unmodified atmosphere at 35 to 37°C with 200 RPM agitation. The 
culture volumes were 20% or less of the manufacturer specified vessel volume, with aluminium 
foil caps. 
2.3.3 Stationary broth 
200µL broth volumes were incubated in the wells of lidded 96-well round bottom polystyrene 
tissue culture clusters (Corning, 3799), in a humidified atmosphere at 35°C with 5% CO2, for 
the specified time.   
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2.4 Storage and revival of cultures 
For long term storage, bacterial isolates were grown on CA for 6-12 hours then suspended in 
SMM to an absorbance of approximately 4 (OD600). Later, cultures were revived from -80°C 
by incubation on chocolate agar. 
2.5 Evaluation of bacterial growth 
2.5.1 Viable counts 
Ten-fold serial dilutions of bacterial suspensions were prepared in DPBS then 100µL aliquots 
spread on CA. Colony counts between 30 and 300 were used to calculate the bacterial density 
in the initial suspension.  
2.5.2 Absorbance  
Absorbance of bacterial suspensions was in a cuvette with a 10mm path length at a wavelength 
of 600nm, with a spectrophotometer (Eppendorf, Biophotometer). In the case of experiments 
with 96 well plates, a microplate reader (Molecular Devices, Spectramax M2) was used, with 
absorbance measured at a wavelength of 600nm. 
2.5.3 Estimation of viable count from absorbance 
The biomass of H. haemolyticus isolate BW1 in sBHI broth was monitored over a 48 hour 
period, by measurement of viable counts and absorbance (OD600) (Fig 2.1). For the period 
between 2.5 hours and 9.3 hours, the growth was logarithmic, and could be represented by the 
linear equation, log (CFU/mL) = 1.26 (log OD600) + 8.86 (Fig. 2.2), which was used, where 
indicated, for estimation of viable count from absorbance (OD600).  
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Fig. 2.1. Growth of NIS producing H. haemolyticus. Isolate BW1 grown on chocolate agar for 12 
hours was used to inoculate 200mL of prewarmed sBHI to an absorbance of 0.03 (OD600), with a 
viable count of 4.8 x 107 CFU/mL, then incubated in a 2L baffled flask for 48 hours at 200 RPM, 
37°C for 48 hours.  
 
Fig. 2.2. Standard curve for calculating viable count of BW1 from absorbance. NIS-producing H. 
haemolyticus isolate BW1 grown on chocolate agar for 12 hours was used to inoculate 200mL of 
prewarmed sBHI to an absorbance of 0.03 (OD600), which was also measured at 4.8 x 107 CFU/mL, 
then incubated in a 2L baffled flask for 48 hours at 200 RPM, 37°C. Line of best fit shown for 
growth phase only, between 2.5 and 9.3 hours. 
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2.6 Agar well diffusion assay 
An agar well diffusion assay was developed for detection and relative quantitation of 
antimicrobial substances, using a previously described method (Schillinger and Lücke, 1989), 
but modified for growth of Haemophilus spp. The media in the plates and the overlay consisted 
of 18.5g/L Brain Heart Infusion (Oxoid, CM1135) solidified with 7.5g/L Bacteriological Agar 
(Oxoid, LP0011) and supplemented with 1% (v/v) resuspended Vitox (Oxoid, SR0090), along 
with 7.5mg/L each of NAD and haematin (Oxoid, SR0158). These media components are at 
half the normal concentration. Into 90mm diameter Petri dishes, 10mL of molten media was 
added with a 25mL serological pipette, and stored at room temperature for 72 hours prior to 
use or storage at 4°C for up to 8 weeks, prior to use. Overlay media of the same composition 
was prepared in 30mL aliquots in 50ml “Falcon” centrifuge tubes, and similarly stored before 
use. To set up an assay, overlay media in 50mL tubes was heated in a 500mL plastic beaker, 
surrounded by water, in a microwave oven, until fully melted, then transferred to a 45°C water 
bath for 15 to 60 minutes. To 5mL of this media, 100µL of 1 x 106 CFU/mL of indicator strain 
suspension (see below) was mixed in, then overlayed on a petri dish of solidified media. The 
plates were then left at room temperature for 30 minutes, then 5mm diameter circular holes 
were cut in the agar using a sterile stainless steel cork borer. Into the wells were added 25µL 
aliquots of the test solutions. The plates were then left open in a biological safety cabinet for 
one hour, at which time there was no longer any free liquid in the wells. Plates were incubated 
for 18-24 hours, except on the occasions that H. haemolyticus was used as an indicator strain, 
in which case incubation was for 44-48 hours. After incubation, diameters of clearing zones 
were measured, with results reported in terms of annular radii of clearing zones, which were 
calculated by subtracting 5mm from the clearing zone diameter, then dividing by 2. 
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Indicator strains for the agar well diffusion assay were prepared by growing for 6-12 hours on 
CA then suspending in DPBS to an absorbance of 1.0 (approx. 1 x 109 CFU/mL), which was 
then diluted 10 fold with SMM, and 100µL aliquots stored in microcentrifuge tubes at -80°C.  
For use, an aliquot was thawed, vortexed briefly, then 5µL mixed with 500µL of DPBS. From 
this suspension, for each agar well diffusion assay plate, 100µL of this 1 x 106 CFU/mL 
suspension was mixed with 5mL of molten overlay media, as described above. In most cases 
the indicator strain was NTHi, strain NCTC 4560 and/or NCTC 11315. 
In the development of the agar well diffusion assay, we found experimentally that reliable 
clearing zone formation could only be achieved when assay was set up exactly as described 
above, with the most important factors being the reduced media concentration and volume, and 
storage of the media for an extended period. Additionally, the clearing zone size was related to 
the media age, such that the older the media, the larger the zone size, but also the smaller the 
size of individual colonies of the indicator strain. As a result of this ageing effect on the media, 
within-experiment comparison should only be made with media of one age.  
2.7 Enrichment of cell-free culture broth  
Ammonium sulfate precipitation was used for the enrichment of cell-free culture broth, and 
was based on the procedure described for haemocin (Venezia et al., 1977). Firstly cell-free 
culture broth was prepared by centrifugation at 7,000 × g for 15-30 minutes, then ammonium 
sulfate (Sigma-Aldrich, A-5132) slowly added and dissolved with continuous stirring, to the 
required % saturation at 4°C (Table 2.1). Solutions were then stored at 4°C for at least two 
hours, centrifuged at 7,000 × g for 20 minutes, and fractions separated and used as appropriate 
for the application.  
  
  Chapter 2. General Materials and Methods 
22 
 
 
Table 2.1. Ammonium sulfate quantities required to be added to 100mL of solution, for fractional 
saturation of aqueous solutions, at 4oC. From http://www.encorbio.com/protocols/AM-
SO4.htm. 
% Saturation Ammonium sulfate (g) 
10 5.3 
20 11.0 
30 17.0 
40 23.3 
50 30.1 
55 33.7 
60 37.3 
70 45.0 
80 53.3 
90 62.1 
 
2.8 Dialysis  
Dialysis in all cases was conducted with 3500 Da molecular weight cut off snakeskin tubing 
(Thermofisher, 68035). Solutions were dialysed for 24 hours at 4°C against 50mM Tris-HCl 
pH 7.5, unless otherwise indicated. Mixing was continuous, and the buffer volume was at least 
100x the test solution volume, and was changed 3 times in the 24 hours, with at least 2 hours 
between each buffer change.  
2.9 Enrichment by ultrafiltration  
Ultrafiltration was conducted to concentrate NIS activity, using a 10 kDA molecular weight 
cut off centrifugal filter unit (Merck, UFC901024). Centrifugation was at 4000 × g for 15 
minutes unless otherwise indicated. 
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2.10 Extraction of genomic DNA  
All isolates were grown overnight on chocolate agar (Oxoid, PP2002) then DNA extracted with 
a DNeasy Blood & Tissue Kit (Qiagen, 69504) in accordance with kit instructions. The 
concentration and purity of DNA extracts were assessed with a Nanodrop 1000 
spectrophotometer. 
2.11 Electrophoresis  
PCR products and gDNA were visualised by electrophoresis in 1.5% agarose made up in TAE 
buffer with SybrSafe. Electrophoresis was for 30 minutes at 100V, and products were 
visualised on a UV transilluminator. 
2.12 SYBR Green Real-time PCR (RTPCR) 
Each RTPCR was a total volume 15µL in 0.1mL tubes (Qiagen, 981103), and contained 100pg 
of template, 333nM each primer (Geneworks, South Australia), and 7.5µL SensiFAST SYBR 
(Bioline, BIO-98005). Thermocycling (Qiagen, Rotor-Gene Q) consisted of an initial melt at 
95°C for 3 minutes followed by 40 cycles of 95°C for 10s, 60°C for 10s and 72°C for 10s. Data 
was acquired at 72°C, and a melt curve constructed between 60 and 95°C. 
2.13 Sanger sequencing 
PCR products and plasmids were sequenced at the Australian Genome Research Facility, 
Melbourne node. 
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 Chapter 3.  
Identifying H. haemolyticus and H. influenzae by SYBR Green 
real-time PCR assays 
This contents of this chapter were submitted for publication in the Journal of Microbiological 
Methods, as an original research article.  It was subsequently revised into a note form, and 
published in the same journal (original submission 11 December 2014; revision submitted 4 
March 2015; accepted 5 March 2015; available online 6 March 2015; volume 112 pp. 67-69; 
DOI: 10.1016/j.mimet.2015.03.001). This chapter is a compilation of the first and revised 
submissions, with the formatting adjusted for incorporation into this thesis.  
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3.1 Introduction 
H. influenzae is an opportunistic bacterial pathogen of humans, with the upper respiratory tract 
its reservoir. H. haemolyticus is a bacterium that is also a resident of the upper respiratory tract 
of healthy people, and has been very occasionally causative of sterile site infections, however 
in the clinical setting it is generally assumed to be normal flora and non-pathogenic (Murphy 
et al., 2007). These bacteria are genetically and phenotypically closely related, both being 
dependent on X and V growth factors. Traditionally these bacteria have been distinguished 
using conventional culture-based methods, utilizing lysis of horse blood to identify H. 
haemolyticus. However, in a landmark study (Murphy et al., 2007) molecular methods were 
used to show that up to 40% of conventional culture identified H. influenzae isolates from 
respiratory specimens were in fact H. haemolyticus. Other studies have similarly shown this 
misidentification, albeit at lower rates. As a result, conventional culture is not reliable for 
identifying these bacteria, and improved methods are required.  
DNA-DNA hybridization, and more recently 16S rRNA gene sequencing, are the gold 
standards for identifying bacteria (Janda and Abbott, 2007; Stackebrandt and Goebel, 1994). 
However these methods are both time consuming and costly, the former particularly so. 
Recently, Matrix Assisted Laser Desorption/Ionization (MALDI-TOF) has been implemented 
in diagnostic laboratories for bacterial identification. Though initially problematic due to 
inadequate manufacturer databases, differentiating H. influenzae and H. haemolyticus is now 
possible with relatively high accuracy (Frickmann et al., 2013; Zhu et al., 2013). The main 
advantages of MALDI-TOF are that it is rapid and the on-going costs are low, however the 
initial equipment costs are prohibitively high for many research laboratories.  
Optimally, assays for identification of H. influenzae and H. haemolyticus would be 
inexpensive, rapid, readily available, and have 100% sensitivity and specificity.  PCR-based 
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assays have the potential to fulfil all these criteria, but none so far have, for these bacteria.   
Conventional PCR methods (Binks et al., 2012; Norskov-Lauritsen, 2009; Theodore et al., 
2012) utilize gel electrophoresis, which is time consuming.  Real-time PCR (RTPCR) methods 
have been developed (Abdeldaim et al., 2009, 2013; Wang et al., 2011) but have so far have 
been limited by their sensitivity and specificity, and make use of hydrolysis probes which can 
be costly and problematic to obtain. High resolution melt PCR (HRM-PCR) assays have been 
developed, and are rapid and inexpensive, but so far they are not sufficiently specific (Binks et 
al., 2012) or sensitive (Pickering et al., 2014), and we were not able to reproduce the results in 
our laboratory. SYBR Green RTPCR assays are inexpensive, rapid and readily available, and 
have been developed for the identification of other bacterial species (Alfaresi and Elkosh, 2006; 
Clifford et al., 2012; Fukushima et al., 2003), but none so far have been developed for the 
identification of H. haemolyticus and H. influenzae.  
Gene targets that identify H. influenzae and differentiate it from H. haemolyticus have been 
described. Several reports have shown that fuculose kinase (fucK) is suitable (Abdeldaim et al., 
2009, 2013; Binks et al., 2012; Norskov-Lauritsen, 2009; Theodore et al., 2012) as it is present 
in most H. influenzae isolates but not H. haemolyticus. Protein D (hpd) is present in both 
species, but substantial sequence variability between the two has made it possible to design 
primers and probes specific for H. influenzae  (Binks et al., 2012; Hare et al., 2012; Pickering 
et al., 2014; Theodore et al., 2012; Wang et al., 2011).  
The number of studies on gene targets for the identification of H. haemolyticus is quite limited 
compared with H. influenzae, as there is more research interest in the pathogenic species. Super 
oxide dismutase C (sodC) has been reported as a suitable target (Fung et al., 2006), however 
there are reports that sodC is also present in a minority of NTHi  (McCrea et al., 2010b; 
Norskov-Lauritsen et al., 2009), which may limit its usefulness in this application. In a recent 
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study (Pickering et al., 2014), H. haemolyticus hpd (Hh-hpd) was shown useful for its 
differentiation from NTHi, as it is present in most isolates, and is sufficiently divergent from 
H. influenzae hpd (Hi-hpd). 
The aim of this study was to improve upon the methods available in research laboratories to 
positively identify H. haemolyticus and H. influenzae. To address this aim we designed and 
tested specific SYBR Green RTPCR assays for both species, using gene targets fucK and Hi-
hpd for H. influenzae, and sodC and Hh-hpd for H. haemolyticus. 
3.2 Materials and Methods 
3.2.1 Bacterial strains 
To assess the performance of the RTPCR assays we tested them against a collection of 127 H. 
influenzae and 60 H. haemolyticus. Within this collection, the H. influenzae organisms 
consisted of 119 clinically relevant NTHi isolates, originating from respiratory tract specimens 
at Australian hospitals, and an additional eight reference strains, ATCC 9007, ATCC 43163, 
ATCC 10211, ATCC 49766, NCTC 8468, NCTC 4560, NCTC 11315, 86-028 NP. The H. 
haemolyticus organisms consisted of 59 isolates from oropharyngeal swab contamination at 
Australian hospitals, and ATCC 33390.  
The identity of all bacterial isolates was confirmed by sequencing of their 16S rDNA. Universal 
primers 27F (5’-AGAGTTTGATCMTGGCTCAG-3’) and 1492R (5’-
TACGGYTACCTTGTTACGACTT-3’) were used to amplify a 1466bp fragment of the 16S 
rDNA which was then sequenced with 27F. After manual inspection of chromatograms the 
sequences were trimmed to 751bp.  The species were then determined by comparison with the 
Genbank database using the blastn algorithm. For this study the search database was restricted 
to sequences from two publications that included large collections of H. influenzae and H. 
haemolyticus  (Murphy et al., 2007; Theodore et al., 2012).  
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3.2.2 Primer Design and SYBR Green real-time PCR 
Primers for the RTPCR assays (Table 3.1) were designed using alignments of Genbank 
nucleotide database sequences for hpd, fucK and sodC. For the hpd assays, Genbank was 
interrogated in March 2014 with search terms “Haemophilus AND hpd”, with all resulting H. 
influenzae and H. haemolyticus sequences aligned, and primers specific for H. influenzae (Hi-
hpd) and H. haemolyticus (Hh-hpd) selected. For the H .haemolyticus sodC specific primers, 
the same procedure was used, except with search terms “Haemophilus AND sodC”, with 
primers specific for H. haemolyticus selected 1 .  Primers for fucK were designed using 
alignments of sequences from a search of Genbank nucleotide database with search terms 
“Haemophilus AND influenzae and fucK”. The specificity of primers was then verified with 
blastn searches in Genbank. Conditions for the RTPCR assay are shown in Chapter 2.12.  
  
                                                          
 
1 A minority of non-typeable H. influenzae sodC sequences, GU269227, GU269224, GU269216 and GU269206, 
could not be discriminated from H. haemolyticus sodC with this primer set. 
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Table 3.1 Primers for identification of H. haemolyticus and H. influenzae. 
Name Sequence, 5' to 3' Target gene Amplicon (bp) 
sodC F GTGCGGTATGTTCAGTTG 
H. haemolyticus sodC 163 
sodC R AGGCCATAGTTAGATTCAGTAAT 
fucK F TCAATGCTCACTSAACGCTTAAC 
H. influenzae fucK 150 
fucK R ACGCATAGGAGGGAAATGGT 
Hi-hpd F AAGGGTTATTGGGTAAACTATA 
H. influenzae hpd  131 
Hi-hpd R TCAGGTTTGGATTCTTCTTTATTA 
Hh-hpd F GCGAAAGGTMAATGGGTAAACTAC 
H. haemolyticus hpd 156 
Hh-hpd R TAATGGTGTGTAKACAATGTT 
 
3.3 Results  
The RTPCR results for the 119 NTHi isolates originating from Australian hospitals (Table 3.2) 
showed that 108 (91%) were positive for both Hi-hpd and fucK, with the remaining 11 (9%) 
positive for only Hi-hpd or fucK. The eight H. influenzae reference strains (Table 3.3) were 
positive for both Hi-hpd and fucK. No H. influenzae were positive for Hh-hpd or sodC.  
For the 59 H. haemolyticus isolates from Australian hospitals, the RTPCR results (Table 3.2) 
showed that all were positive for Hh-hpd, and 56 (95%) were also positive for sodC. The H. 
haemolyticus strain ATCC 33390 was positive for both sodC and Hh-hpd (Table 2), and no H. 
haemolyticus organisms were positive for Hi-hpd or fucK. 
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Table 3.2. Genotype of NTHi and H. haemolyticus originating from Australian hospitals.  
No. (%) fucK Hi-hpd sodC Hh-hpd 
A. NTHi, 
108 (91) + + - - 
5 (4) + - - - 
6 (5) - + - - 
B. H. haemolyticus 
56 (95) - - + + 
3 (5) - - - + 
 
Table 3.3. Genotype of reference strains used in this study. 
strain 
species-type fucK Hi-hpd sodC Hh-hpd 
ATCC 9007 
 Hic + + - - 
ATCC 43163 
Hib + + - - 
ATCC 10211 
Hib + + - - 
NCTC 8468 
Hib + + - - 
NCTC 4560 
NTHi + + - - 
NCTC 11315 
NTHi + + - - 
ATCC 49766 
Hib + + - - 
86-028 NP 
NTHi + + - - 
ATCC 33390 
H. haemolyticus - - + + 
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Sensitivities and specificities for the RTPCR assays were calculated (Table 3.4). All primers 
were 100% specific, with sensitivities ranging from 95% to 100%. For H. influenzae 
identification, fucK, Hi-hpd, fucK and/or Hi-hpd, assay sensitivities were 96%, 95%, 100% 
respectively, and for H. haemolyticus, Hh-hpd, and sodC assay sensitivities were 100%, and 
95%, respectively.  
Table 3.4. Sensitivity and specificity of RTPCR assays in this study. 
RTPCR assay(s) sensitivity % specificity % 
fucKa 96 100 
Hi-hpda 95 100 
fucKa and/or Hi-hpda 100 100 
sodCb 95 100 
Hh-hpdb 100 100 
 
a specific for H. influenzae  
b specific for H. haemolyticus 
Analysis of the RTPCR data showed in all cases that a positive reaction resulted in a single 
melt peak with a cycle threshold between 13 and 18.  
3.4 Discussion 
The aim of this study was to develop assays for the identification of H. influenzae and H. 
haemolyticus, using SYBR Green RTPCR assay technology, as it is a method that is rapid, 
inexpensive and readily available.  
Two primer sets for the identification of each organism were designed, with the assays for H. 
influenzae targeting fucK and Hi-hpd, and H. haemolyticus assays targeting Hh-hpd and sodC. 
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Using these assays we were able to correctly identify all the isolates in a collection consisting 
of 127 H. influenzae and 60 H. haemolyticus organisms, and as such our results support the use 
of our SYBR Green RTPCR assays for the identification of H. haemolyticus and H. influenzae 
in laboratories in which probe-based RTPCR or MALDI-TOF assays are not available.  
The specificities and sensitivities of the assays in our study were broadly consistent with other 
studies that target the same genes, however there were some inconsistencies. In our study, 95% 
of the clinically relevant NTHi from Australian hospitals were positive for fucK (Table 3.2), 
exactly matching the proportion reported in a collection of 480 clinically relevant H. influenzae 
(Norskov-Lauritsen, 2009), and close to the 100% reported for 22 strict NTHi carriage isolates 
(Binks et al., 2012). These proportions are all substantially higher than the 64% reported in a 
study of NTHi carriage isolates (Theodore et al., 2012), which we suggest may have been due 
to the use of crude DNA as template in that study. 
The results from our RTPCR assays showed that all NTHi in our collection from Australian 
hospitals were negative for sodC. This is consistent with most (Fung et al., 2006; Langford et 
al., 2002; Norskov-Lauritsen, 2009; Norskov-Lauritsen et al., 2009; Zhang et al., 2014) but not 
all studies (Langford et al., 1992; McCrea et al., 2010b). However, we had anticipated there 
would be amplification of sodC in the NTHi using our primers, since during the primer design 
phase we had exploited the reported 5% dissimilarity of sodC in H. haemolyticus and NTHi  
(McCrea et al., 2010b). Additionally, our primer design would have excluded amplification of 
sodC in any unexpected isolates of the other known sodC positive H. influenzae, phylogenetic 
division II (Kroll et al., 1991) and the cryptic genospecies biotype IV strains (Langford et al., 
2002), which we accomplished using the 15% dissimilarity between the sodC of H. 
haemolyticus and these H. influenzae (McCrea et al., 2010b) 
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The proportion of sodC positive H. haemolyticus in our study was 95%, which differs from the 
100% reported in the H. haemolyticus collections of other studies. However, as the largest of 
those collections numbers only 110 isolates, and are from a different country, it conceivable 
our collection had a slightly lesser proportion of sodC positive H. haemolyticus. 
In this study, the SYBR Green Hi-hpd RTPCR assay had a sensitivity of 95%, which is within 
the range of sensitivity values reported elsewhere, 88.5% to 98% (Binks et al., 2012; Theodore 
et al., 2012; Wang et al., 2011) for the frequently used hpd# 3 hydrolysis-probe RTPCR assay 
(Wang et al., 2011). The sensitivity of 96% for an HRM-PCR for identification of H. influenzae 
with hpD (Pickering et al., 2014) was a remarkably similar value to that of our assay. 
Also, our Hi-hpd assay was 100% specific, a value higher than reported in most other studies 
which used hpd for identification of H. influenzae (Binks et al., 2012; Pickering et al., 2014; 
Theodore et al., 2012; Wang et al., 2011). We attribute this to primer design, as a larger number 
of H. influenzae and H. haemolyticus hpd sequences were available in Genbank at the time we 
designed our primers. In support of this, the probe-based hpd#3 and hpd#1 RTPCR assays 
(Wang et al., 2011) had differing specificities when tested on the same isolate collection, with 
the hpd#1 assay achieving 100% specificity. Interestingly, in that study the hpd#1 was 
abandoned in favour of the hpd#3 assay, due to it being more suited to use in clinical specimens, 
as less genome equivalents per reaction were required for a positive reaction. However, in 
subsequent studies with isolates, hpd#1 has still not been used, in spite of its apparent greater 
specificity.  As are result, we suggest that the use of hpd#1 should be reconsidered for the 
identification of H. influenzae isolates, when hydrolysis probes are preferred over SYBR Green 
RTPCR assays. . 
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 Relevant to the selection of hpd as a target for the detection and identification of H. influenzae, 
is use of PHiD-CV vaccines. These vaccines, which mainly target Streptococcus pneumoniae 
antigens, also contain H. influenzae protein D, and there is limited evidence that their use has 
reduced the incidence of infection due to NTHi (Prymula et al., 2006; Tregnaghi et al., 2014). 
However, the existence of a subset of disease-associated true NTHi strains that are clearly 
deficient in hpd has been shown (Smith-Vaughan et al., 2014) and while none of these strains 
were from PHiD-CV vaccinated individuals, a concern remains that continued use of these 
vaccines may select for these strains. Were such an increase in prevalence of hpd-deficient 
NTHi to occur, any efficacy of the vaccines against NTHi would likely be reduced, as would 
the usefulness of hpd as a target for NTHi identification. 
Our Hh-hpd assay is the first report we are aware of that uses hpd for the identification of H. 
haemolyticus. However it appears the HRM-PCR assay (Pickering et al., 2014) could also be 
used in this application, but was not reported as such, as the majority of researchers in this field 
are interested only in the correct identification of H. influenzae. However in our laboratory the 
reported performance of the HRM-PCR was difficult to reproduce, and as such we cannot 
recommend its use. 
The degree to which the results of our study can be extended to H. influenzae and H. 
haemolyticus more broadly is limited by the relatively restricted origin of our isolates. Our 
collection consisted of H. influenzae and H. haemolyticus isolates from Australian hospitals 
only. However, that our results were generally consistent with assays that target the same genes, 
conducted on isolates from other countries (Abdeldaim et al., 2013; Fung et al., 2006; McCrea 
et al., 2010b; Norskov-Lauritsen, 2009; Theodore et al., 2012; Wang et al., 2011) leads us to 
the believe that in practice this limitation will be minimal. 
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This study reinforces the previously reported utility of hpd, fucK and sodC for the identification 
of H. influenzae and its differentiation from H. haemolyticus, and improves upon previously 
described methods, by making use of SYBR Green RTPCR assays , which are relatively rapid, 
inexpensive and readily available than other published assays commonly used in research 
laboratories.  
Our study is a significant advance for the laboratory identification of H. haemolyticus, as it 
describes sensitive and specific PCR targets. This allows the organism to be positively 
identified rather than identity being assumed by default based on exclusion of H. influenzae, 
as is often the case. 
Identification of an organism as H. haemolyticus or H. influenzae could in most cases be 
achieved unambiguously with just two of our SYBR Green RTPCR assays; a single positive 
RTPCR result for a sequence specific to one organism, accompanied by a single negative result 
to the other organism. However, as H. influenzae and H. haemolyticus have very significant 
genomic heterogeneity, appear to be in an evolutionary continuum (Binks et al., 2012), and can 
undergo interspecies recombination (Witherden et al., 2014), we suggest the use of all four 
assays, with 16S rDNA sequencing reserved for ambiguous results. This suggestion of multiple 
targets is in agreement with other workers in this field that caution no single target is likely to 
be a perfect diagnostic for either species (de Gier et al., 2016; Pickering et al., 2014; Price et 
al., 2017).  
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 Chapter 4.  
Phenotypic detection of NTHi inhibiting substances (NIS) 
produced by H. haemolyticus 
The results in this chapter, for the agar well diffusion assay testing of enriched cell-free culture 
broths, were incorporated into the publication “An isolate of Haemophilus haemolyticus  
produces a bacteriocin-like substance that inhibits the growth of nontypeable Haemophilus 
influenzae” by Latham, R. D., Gell, D. A., Fairbairn, R. L., Lyons, A. B., Shukla, S. D., Cho, 
K. Y., . . . Tristram, S. G.’ which was published in the International Journal of Antimicrobial 
Agents in April 2017 (doi:10.1016/j.ijantimicag.2016.12.010).  
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4.1 Introduction 
NTHi, as discussed previously (Chapter 1.2), frequently colonize the upper respiratory tract of 
healthy children and adults, and are also a major cause of self-limiting opportunistic respiratory 
infections (Van Eldere et al., 2014). Also, NTHi are increasingly causative of invasive diseases, 
including septicaemia and meningitis, particularly in infants (Langereis and de Jonge, 2015). 
With the increasing resistance to antimicrobial therapy, for the management of NTH infections 
(Dabernat and Delmas, 2012), treatment options are becoming limited. Also, an effective 
vaccine has yet to be developed (Khan et al., 2016; Teo et al., 2017).  In this landscape, 
alternatives for the prevention and/or treatment should be considered.  
Probiotics for the respiratory tract have been developed for the prevention of infections caused 
by S. pyogenes (Di Pierro et al., 2012), S. pneumoniae (Marchisio et al., 2015) and N. 
meningitidis (Deasy et al., 2015), but not against NTHi. H. haemolyticus is a commensal of the 
upper respiratory tract, and as such, partially fulfils the requirements as a probiotics against 
NTHi (Dunne et al., 2001). The potential of H. haemolyticus as a probiotic against NTHi was 
discussed recently in a study which showed H. haemolyticus preventing the attachment of 
NTHi to epithelial cells (Pickering et al., 2016). However, to have probiotic function, strains 
of H. haemolyticus should also secrete NTHi-inhibiting substances (Dunne et al., 2001). But 
as secretion of an NTHi-inhibiting substance (haemocin) by a closely related organism has 
already been shown (Venezia,and Robertson, 1975), it is reasonable to suspect that some H. 
haemolyticus may also produce similar substances, and we consider that investigation of this 
phenomenon is warranted. 
In this study, to further investigate the probiotic potential of H. haemolyticus, we qualitatively 
tested H. haemolyticus isolates for production of NTHi inhibiting substances (NIS), by 
screening for inhibitory activity in co-culture and agar well diffusion assays. 
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4.2 Materials and Methods 
4.2.1 H. haemolyticus collection 
The H. haemolyticus collection was composed of 100 randomly selected isolates originating 
from respiratory specimens submitted to Australian diagnostic laboratories, and throat swabs 
of healthy volunteers, along with reference strain ATCC 33390. All isolates were identified by 
16S sequencing and SYBR Green Real Time PCR for species specific markers, as described in 
Chapter 3 and elsewhere (Latham et al., 2015). Of these 100 isolates, 61 were randomly chosen 
for the initial co-culture screening for evidence of inhibitory activity, in which H. haemolyticus 
isolates were pre-incubated prior to addition of H. influenzae indicator strains. The second 
assay, co-culture with simultaneous incubation, tested only the positive isolates from the initial 
co-culture screening assay.  For the third assay, an agar well diffusion assay was used to screen 
the full collection of 100 isolates for NIS production. 
4.2.2 Co-culture assay: Screening pre-incubated H. haemolyticus for inhibition of NTHi.  
The first method of screening for NIS was a co-culture plate assay, and was a modification of 
the plate assay method described for the discovery of haemocin (Venezia and Robertson, 1975). 
Our approach differed in that the test isolates of H. haemolyticus were pre-incubated on the 
plates, and the indicator strains were spot inoculated onto the H. haemolyticus colonial growth, 
rather than being spread over the entire plate. This modification was required because the H. 
haemolyticus growth rate was less than that of H. influenzae. 
In our assay, the colonial growth of H. haemolyticus test isolates were assessed for inhibition 
of growth of a mixture of H. influenzae reference strains. The test isolates were first grown on 
chocolate agar (CA) then suspended in DPBS to an absorbance of 1.0 (OD600). This suspension 
was streaked in 5cm lengths on CA plates with a calibrated 10µL plastic inoculation loop, with 
three streaks to a plate. After incubation of the streaks for 20 hours, a mixed suspension 
  Chapter 4. Phenotypic detection of NIS 
39 
 
consisting of equivalent amounts (OD600) of overnight cultures of the H. influenzae indicator 
strains NCTC 11315 (NTHi), ATCC 10211 (Hib), ATCC 43163 (Hib), ATCC 49766 (NTHi), 
ATCC 9007 (HiC), NCTC 4560 (NTHi), NCTC 8468 (Hib), Rd KW20 (Hid), 86-028NP 
(NTHi), was prepared in DPBS, to an absorbance of 1.0 (OD600). 10µL aliquots of this 
suspension were dropped onto the centre of the H. haemolyticus colonial growth streaks, with 
the suspension flowing without aid onto the media adjacent to the colonial growth, in a circular 
shape of 5 to 10mm diameter. Another 10µL drop of the mixed H. influenzae suspension was 
placed on the plate, but away from the streak, to serve as a growth control. The assay set up is 
diagrammatically represented below (Fig. 4.1). After incubation for a further 20 hours, H. 
influenzae growth was examined. 
 
 
 
 
 
 
 
Fig. 4.1. Diagrammatic representation of co-culture assay set up, for the initial screening H. 
haemolyticus isolates for inhibition of NTHi, with test strains pre-incubated. 10µL drops of a 
suspension of mixed H. influenzae indicator strains were placed on the centre of pre-incubated 
streaks of H. haemolyticus test strains. After incubation, H. influenzae growth was examined, with 
inhibitory activity demonstrated by absence of indicator growth on and adjacent to the test strain.  
Indicator strains co-
cultured with pre-
incubated test strain 
Pre-incubated test strain 
Indicator strains, growth 
control 
Legend 
Chocolate agar 
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4.2.3 Co-culture assay: NTHi and H. haemolyticus incubated simultaneously 
The H. haemolyticus isolates that were positive for inhibition of the H. influenzae growth in 
the first co-culture assay were tested for inhibition of NTHi using a co-culture assay with 
simultaneous incubation. The assay was the same as the plate assay method described for the 
discovery of haemocin (Venezia and Robertson, 1975), but with extended incubation, to allow 
for the slow growth of H. haemolyticus. The indicator strain for this assay was the NTHi 
reference strain NCTC 11315, which was grown on CA then suspended in DPBS to an 
absorbance of 0.03 (OD600), with 2.5mL volumes of the suspension spread over plates of sBHI, 
excess liquid removed with a transfer pipette, and the lids then left open until the surface was 
dry. For each plate, the colonial growth of the H. haemolyticus isolates were stab-inoculated 
into the sBHI plate with sterile wooden toothpicks, in a grid pattern (Fig. 4.2) with 11mm 
spacing between each. Twenty-two Hib organisms (MDU isolates 1 to 20, ATCC 8468, ATCC 
10211) were included as positive controls, as they are producers of the NTHi inhibiting 
bacteriocin, haemocin, and the NTHi reference strain NCTC 11315 included as a negative 
control. The plates were examined for absence of growth of the indicator strain around the test 
organisms after 19 hours and 43 hours of incubation.  
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Fig. 4.2. Diagrammatic representation of a co-culture assay,  for screening H. haemolyticus 
isolates for inhibition of NTH, with simultaneous incubation. An NTHi indicator strain, NCTC 
11315 was spread over over supplemented brain heart infusion agar, with H. haemolyticus test 
strains then stab-inoculated. After incubation, the growth of the indicator strain around the test 
strains was examined, with absence of growth indicating inhibitory activity. 
4.2.4 Screening for NIS production by agar well diffusion assay 
An agar well diffusion assay (Chapter 2.6) was developed to further investigate the inhibition 
of H. influenzae that was observed in the initial co-culture screening assay. To obtain a better 
estimate of the prevalence of NIS production, and to increase the possibility of detecting a 
rarely produced NIS, the number of isolates screened was increased, from 61 in the first assay, 
to 100. Each of the wells in the agar contained cell-free culture broth which had been enriched 
for NIS by ammonium sulfate precipitation to increase the likelihood of detecting inhibitory 
activity. H. haemolyticus isolates which tested positive, as shown by the presence of clearing 
zones, were re-tested using new preparations of enriched cell-free culture broth, and only 
isolates that tested positive in both assays are reported as positive for the production of NIS. 
For comparison purposes, 99 randomly chosen NTHi isolates originating from Australian 
diagnostic laboratories (Appendix 1.), along with three NTHi reference strains (ATCC 49766, 
NCTC 4560 and NCTC 11315) were also included in the testing for NIS production.  
Legend 
NTHi indicator 
strain 
Test strain 
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4.2.5 Preparation of cell-free culture broth 
Cell-free culture broths were produced for each isolate, prior to testing in the agar well diffusion 
assays. Isolates were grown for 6-12 hours on CA, suspended in DPBS to an absorbance of 1.0 
(OD600), then 250µL added to 5mL of sBHI in 50-mL non-baffled flasks. These inoculated 
broths were incubated with 200 RPM agitation for 24 hours at 37°C. The cultures were then 
centrifuged at 7000 x g for 30 minutes, and sterile filtered (0.22µm). Cell-free culture broths 
were tested for NIS activity by agar well diffusion assay (Chapter 2.6), or first enriched by 
ammonium sulfate precipitation, then tested for NIS activity by agar well diffusion assay. 
Additionally, enriched cell-free culture broth from the haemocin-producing Hib reference 
strain ATCC 43163 was prepared as a NIS positive control. Indicators of antimicrobial activity 
were NTHi reference strains NCTC 11315 and NCTC 4560.  
4.2.6 Enrichment of cell-free culture broth by ammonium sulfate precipitation 
Cell-free culture broths were enriched for NIS by ammonium sulfate precipitation (Chapter 
2.7), with ammonium sulfate added to 55% saturation (Table 2.1), as was used for the discovery 
of haemocin (Venezia and Robertson, 1975). The resulting ammonium sulfate precipitates were 
dissolved in a volume of DPBS equal to 1/20th the culture broth volume. 
4.3 Results 
Three assay methods were used to test for inhibition of NTHi by H. haemolyticus isolates. 
Initially, 61 isolates were screened using a co-culture assay, with H. haemolyticus pre-
incubated before H. influenzae were added.  In the second assay, six isolates from the first 
assay that were positive for activity were co-cultured simultaneously with NTHi.  For the third 
assay method, an agar well diffusion assay was used to screen cell-free culture broths from 100 
H. haemolyticus isolates, for production of NIS.  
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Using the first co-culture assay, in which 61 pre-incubated H. haemolyticus were screened, six 
isolates (BW1, CF26, L37, L52, L56, M05) inhibited the growth of the mixture of H. influenzae 
reference strains (Table 4.1). The inhibitory activity was observed with naked eye, and seen as 
an absence of indicator strain growth, adjacent to the pre-incubated H. haemolyticus streaks 
(Fig. 4.3A). The other H. haemolyticus organisms did not inhibit the indicator strains, such that 
they grew right up to, and in some cases, over the test strains (Fig. 4.3B, 4.3C). The six isolates 
testing positive for inhibition of H. influenzae were then subjected to further testing in a 
simultaneous incubation co-culture assay. However, they did not inhibit the growth of NTHi 
(Fig. 4.4A.), while the positive control Hib organisms produces small zones of inhibition (Fig. 
4.4B), extending approximately 1mm out from the colonial growth.  
The positive results for the agar well diffusion assay depended on enrichment of activity in the 
cell-free culture broth. No unenriched cell-free culture broth preparations, including the 
positive control Hib strain, inhibited the NTHi indicator strains. Whereas with the use of 
enriched cell-free culture broth, the two H. haemolyticus isolates BW1 and RHH122 
consistently inhibited both indicator strains (Fig. 4.5, only BW1 inhibition of NCTC 4560 is 
shown), while the enriched cell-free culture broth preparations from the other 98 H. 
haemolyticus isolates (Table 4.1), and the 102 NTHi organisms included for comparison 
purposes (Appendix 1.), were negative.  
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Table 4.1. H. haemolyticus isolates inhibiting NTHi. The listed H. haemolyticus were screened for 
inhibition of NTHi by co-culture and/or agar well diffusion assay. For co-culture, isolates were 
pre-incubated on chocolate agar prior to spot inoculation with a suspension of mixed H. influenzae 
reference strains, then re-incubated. For agar well diffusion assay, cell-free culture broths were 
enriched by ammonium sulfate precipitation, then tested against NTHi reference strains NCTC 
4560 and NCTC 11315. Left symbol: result for screening by co-culture assay, right symbol: result 
for screening by agar well diffusion assay, – : negative, + : positive, o : not tested, bold : a positive 
result in either assay. 
ATCC 33390 - - CF69 - - L152 o - RHH11 - - 
  L153 o - RHH13 - - 
BW1 + + L3 o - L187 o - RHH16 - - 
BW2 - - L4 - - L190 o - RHH40 - - 
BW5 - - L5 - - L191 o - RHH57 - - 
BW6 - o L6 - - L274 o - RHH58 - - 
BW15 - - L7 - - L292 o - RHH59 - - 
BW16 o - L8 o - L320 o - RHH61 - - 
BW18 - - L12 - - L345 o - RHH65 - -  
BW33 o - L16 o -  RHH67 - o 
BW34 o - L19 - - M05 + - RHH75 - - 
BW36 o - L23 - - M16 o - RHH112 - - 
BW39 o - L34 o - M22 - - RHH122 - + 
 L37 + - M26 - -  
BWOCT 2 o - L42 o - M28 o - UTAS 161 - o  
BWOCT 3 o - L43 - - M30 o -  
BWOCT 9 o - L47 o - M34 - -  
BWOCT 12 o - L48 - -   
BWOCT 13 o - L50 o - NF1 - -  
BWOCT 14 o - L51 o - NF2 o -  
BWOCT 16 o - L52 + - NF4 - -  
BWOCT 17 o - L54 o - NF5 - -  
BWOCT 18 o - L55 o - NF6 - -  
BWOCT 20 o - L56 + - NF11 - -  
 L61 o - NF14 - -  
CF5 - - L66 - - NF15 - -  
CF14 - - L71 - - NF19 - -  
CF25 - - L72 o - NF22 - -  
CF26 + - L73 o - NF28 - -  
CF28B - - L93 - - NF34 - -  
CF53 - - L95 - - NF36 - -  
CF65 - - L117 o -   
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Figure 4.3. Inhibition of H. influenzae by pre-incubated H. haemolyticus. 10µL droplets of mixed 
H. influenzae suspension were placed on the the middle of preincubated H. haemolyticus streaks, 
and separately (circular colony to the left of the streak) for a growth control, on chocolate agar. 
After incubation, the growth of H. influenzae was assessed visually, with absence of growth 
adjacent to the streak (A) indicating inhibition, and growth on and adjacent to the streaks (B, C) 
indicating no inhibition.  
 
Figure 4.4. Inhibition of NTHi by Hib but not H. haemolyticus, in simultaneous co-culture. The 
growth of NTHi indicator strain NCTC 11315, spread over sBHI agar, was inhibited by all 
simultaneously grown Hib organisms, including MDU 3 (B) but not by the Haemophilus 
haemolyticus  isolate BW1 (A) or any other H. haemolyticus test isolates. 
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Fig. 4.5. Inhibition of NTHi by H. haemolyticus BW1. Growth of NTHi reference strain NCTC 4560 
is inhibited around a well containing enriched cell-free culture broth from H. haemolyticus isolate 
BW1. + is enriched cell-free culture broth from H. influenzae type b reference strain ATCC 43163, 
a positive control for the assay, as it produces haemocin.  – is enriched cell-free culture broth from 
negative control NTHi reference strain NCTC 4560. 
4.4 Discussion  
This study was a preliminary investigation of the potential of H. haemolyticus in the respiratory 
tract to reduce NTHi infection, with the assays intended to show phenotypical evidence for 
inhibition of NTHi growth, as well as NIS production. Using co-culture plate and agar well 
diffusion assays, there was evidence that a minority of H. haemolyticus isolates were able to 
inhibit NTHi, and produce a NIS. In our first co-culture assay, the colonial growth of 6 of 61 
pre-incubated H. haemolyticus inhibited a mixed culture of H. influenzae. However, when these 
six isolates were incubated in co-culture simultaneously with NTHi, no inhibitory activity was 
observed. To further investigate the inhibitory activity observed in the first co-culture assay, 
an agar well diffusion assay was developed to test for NIS in cell-free culture broth from the 
six isolates. Yet, it was only when the cell-free culture broth was enriched for NIS by 
ammonium sulfate precipitation was inhibitory activity observed, and only by a single isolate, 
BW1. Then, using the agar well diffusion assay for screening a larger collection of H. 
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haemolyticus for NIS, we were able to detect one other NIS producer, RHH122, and thus the 
prevalence of NIS production in our H. haemolyticus collection was 2 in 100 (2%).  
Co-culture assays on solidified media, as used in this study, have been used extensively for the 
screening of microorganisms including, Haemophilus spp., for production of antimicrobial 
substances (LiPuma et al., 1990, 1992, Murley et al., 1997, 1998; Venezia and Robertson, 
1975). The advantages of such assays are rapidity and cost effectiveness, and their potential to 
induce the production of antimicrobial substances which would not be produced in 
monoculture (Maldonado-Barragán et al., 2013). In our study, using a co-culture assay in which 
H. haemolyticus test isolates were pre-incubated, 6 of 61 isolates inhibited H. influenzae. 
However, when the inhibiting isolates were tested in a second co-culture assay, which utilised 
simultaneous incubation, the activity was no longer apparent. These observations suggest that 
a large established H. haemolyticus population is required for an inhibitory factor to be 
produced, and as well demonstrate a weakness of the co-culture assay technique - that they 
convey scarce information about the environmental requirements for production of inhibitory 
activity, or the mechanism of the inhibition.  Indeed, the observed inhibitory activity in co-
culture could be due to non-specific mechanisms, such as depletion of nutrients or excretion of 
metabolites. However we consider such a non-specific mechanism unlikely, because only 10% 
of H. haemolyticus inhibited H. influenzae. Nevertheless, we developed the third assay method, 
an agar well diffusion assay, to further investigate the inhibitory activity observed in the first 
assay, and to help establish that NIS was being produced. 
Agar well diffusion assays, as used in this study, are another technique that has been used 
extensively in the investigation of antimicrobial substances, including those produced by 
Haemophilus spp. (He et al., 2006; Schillinger and Lücke, 1989; Streker et al., 1981; Venezia 
and Robertson, 1975; Venezia et al., 1977). A strength of the technique is that it more 
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effectively identifies inhibition effects due to substances produced by organisms, from the 
effects due to depletion of nutrients in the growth media that accompany growth. However, as 
well as being substantially more time consuming, a weakness of this and other indirect 
techniques is that inhibitory substances are being tested in a different environment from which 
they were produced, and as a result do not produce the localised concentration spikes that occur 
when substances are produced in situ. Indeed, as was the case in the discovery of haemocin 
(Venezia and Robertson, 1975), no inhibitory activity could be observed until the cell-free 
culture broth was concentrated 20-fold by ammonium sulfate precipitation. This reduced 
concentration effect may also help explain the difference in estimated prevalence of inhibitory 
activity observed between the assays; 10% for co-culture, and 2% for the agar well diffusion 
assay. 
In this study, there were substantial differences in the results between the two screening assays 
for inhibitory activity.  The differences in prevalence are discussed above, but, more puzzling 
is that the apparently more sensitive initial co-culture screening assays showed RHH 122 did 
not produce NIS, but the agar well diffusion assay screening did. At this stage we do not have 
enough experimental evidence regarding the mechanism of inhibition in either the co-culture 
or agar well diffusion assay for us to explain these differences. However, although these 
differences are informative, and important for future studies in which isolate collections are 
screened for inhibitory activity, it will likely be a moot point for this project, as subsequent 
research will  be dominated by testing of enriched cell-free culture broth preparations, and only 
the agar well diffusion assay will be used.   
Our results are the first we are aware of that show H. haemolyticus can inhibit the growth of 
other bacterial species. However, Haemophilus spp. have previously been shown to inhibit the 
growth of bacterial species, with Hib the archetype, as they produce haemocin (Venezia and 
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Robertson, 1975), a bacteriocin which inhibits NTHi. Interestingly, H. influenzae and H. 
haemolyticus appear to be in an evolutionary continuum (Binks et al., 2012) and can undergo 
interspecies recombination (Witherden et al., 2014), which presents the possibility that 
haemocin genes may be present in both species, and that the observed inhibitory activity of H. 
haemolyticus isolates, was due to production of haemocin. Indeed, as was the case with 
haemocin (Venezia and Robertson, 1975)it was only when the cell-free culture broth was 
concentrated 20-fold by precipitation with 55% saturated ammonium sulfate was inhibitory 
activity detected in the agar well diffusion assay. Even though genetic testing is the preferred 
method of testing, for the following two reasons we suggest our results so far show that our H. 
haemolyticus isolates are unlikely to be producing haemocin. Firstly, in the co-culture 
screening assay, six H. haemolyticus isolates inhibited a mixed culture of H. influenzae, which 
included four Hib strains – an unlikely result if the six H. haemolyticus were producing 
haemocin, as the great majority of Hib are also producers of haemocin (LiPuma et al., 1990) 
and have genes for haemocin immunity (Murley et al., 1997). Secondly, in the simultaneous 
co-culture plate assays, the Hib isolates produced clearing zones, which any haemocin 
producing H. haemolyticus would also be expected to do, but they did not.  
In this study, we observed the inhibition of H. influenzae, including NTHi, by a minority of H. 
haemolyticus organisms. This inhibitory activity appeared to be due the movement of inhibitory 
substance(s) through the growth media. However, we consider it unlikely that this substance 
was haemocin, the bacteriocin produced by Hib. As such our results broadly support the idea 
that some H. haemolyticus organisms exist which could be used as probiotics to inhibit NTHi, 
as has been suggested previously (Pickering et al., 2016).  Nevertheless, at this stage the 
generalizability of the main findings from this study are substantially limited by their in vitro 
nature, and further support for the use of such organisms as probiotics would require that this 
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inhibitory activity still exist in the complex microbial environment of the human respiratory 
tract. To this end, we recommend further studies of the characteristics, structure, production 
and mechanism of action of the NIS produced by H. haemolyticus, and  although so far we 
have compared the inhibitory activity of H. haemolyticus to that of the bacteriocin haemocin, 
it is important to recognise there are other types of diffusible substances that specifically inhibit 
growth of microbes, including siderophore and quorum sensing substances (Hibbing et al., 
2010). 
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Chapter 5.   
Characteristics of an NTHi inhibiting substance produced by H. 
haemolyticus 
The results in this chapter were incorporated into the publication “An isolate of Haemophilus 
haemolyticus produces a bacteriocin-like substance that inhibits the growth of nontypeable 
Haemophilus influenzae” by Latham, R. D., Gell, D. A., Fairbairn, R. L., Lyons, A. B., Shukla, 
S. D., Cho, K. Y., . . . Tristram, S. G.’ which was published in the International Journal of 
Antimicrobial Agents in April 2017 (doi:10.1016/j.ijantimicag.2016.12.010).  
 
 
  
  Chapter 5. Characteristics of a NIS 
52 
 
5.1 Introduction 
In Chapter 4, we showed evidence for production by H. haemolyticus of a diffusible substance 
which inhibited the growth of NTHi. Using a co-culture assay, 6 of 61 H. haemolyticus isolates 
(BW1, CF26, L37, L52, L56, M05) inhibited a mixed culture of H. influenzae, including NTHi.  
Then, using an agar well diffusion assay, growth of NTHi was inhibited by the enriched cell-
free culture broth from the H. haemolyticus isolates, BW1 and RHH122. For the development 
of H. haemolyticus as a probiotic, further characterisation of the NIS produced by H. 
haemolyticus was required. 
In this chapter, we sought to understand the chemical and physical properties of the NIS 
produced by H. haemolyticus BW1 (BW1-NIS). This isolate was selected for further study as 
it was the only H. haemolyticus isolate which showed activity in both the co-culture and agar 
well diffusion assays. Similar to previous studies identifying novel antimicrobial substances 
(He et al., 2006; Venezia and Robertson, 1975), we examined the ammonium sulfate 
concentration required for enrichment, production in relation to bacterial growth, spectrum of 
activity, resistance to inactivation by heat, resistance to inactivation by extremes of pH, 
resistance to degradation by enzymes, and apparent molecular size. Additionally, BW1 gDNA 
was tested for presence of the structural gene for haemocin, hmcA. 
5.2 Materials and Methods 
5.2.1 Assessment of inhibitory activity 
Agar well diffusion assays (Chapter 2.6) were used for the assessment of NIS activity in 
enriched cell-free culture broth (Chapter 2.7), with the NTHi reference strain NCTC 4560 as 
the indicator.  
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5.2.2 Preparation of NIS produced by BW1 (BW1-NIS) 
Cell-free culture broth from H. haemolyticus isolate BW1 was enriched for NIS and used for 
the experiments in this study. Cultures of BW1 were grown on CA for 12-16 hours (except in 
the case of production with time and population experiments), then suspended in pre-warmed 
(37°C) sBHI to an absorbance of 0.05 (OD600). Inoculated broths were then incubated with 200 
RPM agitation for 24 hours at 37°C, and supernatants collected after centrifugation at 7000 x 
g, 30 minutes. Cell-free culture broths were then enriched for NIS (Chapter 2), with ammonium 
sulfate added at 70%, a value chosen from the ammonium sulfate concentration optimisation 
experiments in this Chapter. The precipitates were dissolved in a volume of DPBS equal to 
1/20th of the initial culture broth volume, heated at 90°C for 3 minutes (except in the case of 
testing for resistance to inactivation by heating) for microbial decontamination and denaturing 
of heat labile proteins, then centrifuged at 10,000 × g for 10 minutes, and supernatants collected 
for characterisation experiments. Preparations for chromatographic separations and 
inactivation experiments were also dialysed (Chapter 2.8), concentrated to the pre-dialysis 
volume by ultracentrifugation (Chapter 2.9), and finally passed through a 0.2 µm filter. 
Haemocin was also prepared, from Hib reference strain ATCC 43163, as described previously 
(Chapter 4.2.5). 
5.2.3 Ammonium sulfate concentration optimisation 
Variable amounts of ammonium sulfate were added to a single batch of BW1 cell-free culture 
broth to determine the concentration required for BW1-NIS precipitation. Ammonium sulfate 
was added to 10mL aliquots of cell-free culture broth in 50mL centrifuge tubes, to achieve 
saturations of ranging from 30% to 80% (Table 2.1), dissolved immediately by inversion, and 
processed as described for enrichment of cell-free culture broth (Chapter 2.7). The resulting 
precipitates were dissolved in DPBS as described above, and tested for activity. A separate 
experiment was conducted, to determine if additional activity was recoverable from a 55% 
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saturated solution, as used for enrichment in Chapter 4, by addition of ammonium sulfate to 
70% saturation. 
5.2.4 Production of NIS by BW1 
For assessment of the growth stage at which BW1-NIS was being produced, 5 x 400mL 
volumes of sBHI broths were prepared in 2000-mL baffled flasks, inoculated as described 
above, but with BW1 inoculum culture grown on CA for 10 hours, and a broth incubation time 
of 12 hours. At regular intervals the five flasks were sampled for measurement of absorbance 
(OD600), and assessment of inhibitory activity. Viable counts were calculated from 
absorbances, using an equation from a standard curve (Chapter 2.5.3, Fig. 2.2.).  
5.2.5 Spectrum of activity  
Agar well diffusion assays (Chapter 2.6) were used to determine the activity of BW1-NIS 
against a range of clinically relevant bacteria. Assays were set up with overlayed indicator 
strains variably composed of NTHi (n = 102), Hib (n = 21), H. haemolyticus (n = 30), 
Acinetobacter baumanii (n = 1), Burkholderia cepacia (n = 1), Enterococcus spp. (n = 4), 
Escherichia coli (n = 3), H. parainfluenzae (n = 2), H. influenzae type c (n = 1), Moraxella 
catarrhalis (n = 1), Neisseria lactamica (n = 1), Proteus vulgaris (n = 1), Pseudomonas 
aeruginosa (n = 1), Staphylococcus spp. (n = 4), and Streptococcus spp. (n = 5). For comparison 
purposes, the spectrum of activity of a haemocin preparation from Hib reference strain ATCC 
43163 was determined with the same H. haemolyticus collection (n = 30). 
5.2.6 Resistance to inactivation  
The chemical stability of the active component in BW1-NIS was examined by assessing its 
resistance to conditions which degrade proteins; heat, pH extremes and proteinases. Also, as 
for the original description for haemocin (Venezia and Robertson, 1975), the possibility that 
the antimicrobial activity was due to a bacteriophage was examine, by treatment of BW1-NIS 
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with DNase. For assessment of resistance to heat, three experiments were undertaken. In the 
first experiment, 250µL aliquots of BW1-NIS in pre-heated 1500 µL microcentrifuge tubes 
were incubated for 15 minutes in a heating block at set temperatures of 40°C, 50°C, 60°C, 70°C, 
80°C, 90°C, and 100°C, centrifuged at 16,000 x g for 10 minutes, to pellet the resulting 
suspending precipitates, and supernatants tested for activity. In the second heating experiment, 
100 µL aliquots of BW1-NIS in 1500 µL microcentrifuge tubes were heated for 2 hours in a 
dry heating block set to 95°C, with actual solution temperatures continuously measured using 
a thermometer in a blank tube, which contained 100µL of water. Tubes were removed from the 
heating block at intervals of 7, 10, 20, 30, 60 and 120 minutes from commencement of 
incubation. For the third heating experiment, 4 x 40µL aliquots of BW1-NIS were autoclaved 
in plastic 200µL PCR tubes at 110°C for 15 minutes. Resistance of 200µL aliquots of BW1-
NIS to inactivation by pH extremes was determined by adjusting the pH to values of 1.6, 2.1, 
3.3, 4.5, 5.3, 6.4, 7.2, 7.9, 8.6, 9.1, and 9.7 with a calibrated ISFET pH meter (Shindengen, 
IQ25 Mini) and 0.1M and 1.0M solutions of HCl and NaOH, incubating for 1 hour at room 
temperature, neutralizing back to pH 7.2, then equalizing the volumes with DPBS. Resistance 
to enzymatic degradation was determined by addition of enzymes to a final concentration of 1 
mg/mL, using proteinase K (Bioline, BIO-3708), 1 mg/mL Trypsin (Sigma-Aldrich, T4049) 
and 100U/mL DNAse I (Invitrogen, 18068015). The enzyme containing solutions were 
incubated at 37°C for 20 hours, heated at 90°C for 3 minutes for microbial decontamination, 
centrifuged at 16,000 x g for 10 minutes, and supernatants tested for activity.  
5.2.7 Molecular size 
The molecular size of the active component in BW1-NIS was estimated by size exclusion 
chromatography (SEC). BW1-NIS was fractionated with a calibrated HiLoad 26/600 Superdex 
200 column (GE Healthcare Life Sciences) with a bed volume of 320mL and a sample load of 
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10mL, equilibrated in 0.15M sodium phosphate buffer, pH 7.0. The column was calibrated 
with native globular proteins, thyroglobulin (670 kDa), γ-globulin (158 kDa), ovalbumin (44 
kDa), and myoglobin (17 kDa), as standards (Bio-Rad, Hercules).  
5.2.8 Real-time PCR for haemocin 
DNA was extracted from BW1, and tested for the presence of the Hib haemocin structural gene 
(hmcA) by RTPCR (Chapter 2.12)  of a 151bp fragment with primers 2533F (5’- 
CAGCTTCGCTAGCAAGTAGTAATG-3’) and 2683R (5’-
TGTTTTGCTCCGCATATTGA-3’) designed from the Hib haemocin locus (accession no. 
U68399).  
5.3 Results 
Ammonium sulfate precipitation is a method that is commonly used to selectively enrich 
peptides or proteins from complex and dilute mixtures, early in a purification procedure. Two 
experiments were set up to determine the ammonium sulfate concentration required to enrich 
BW1-NIS in cell-free culture broth. In the first, no activity was detectable at saturations of 30% 
and 40%, inhibitory activity was detectable at 50% saturation, and the maximum activity was 
recovered at saturations of 60%, 70% and 80% (Fig. 5.1). In the second experiment, working 
with a 55% saturated solution, addition of ammonium sulfate to 70% saturation resulted in the 
recovery of a similar amount of activity to that which was recovered from the 55% saturation 
precipitate. As a result of these two experiments, and to maximise recovery, a saturation of 
70% was used for enrichment of BW1-NIS in all other experiments in this chapter.  
The production of BW1-NIS was measured over a 12 hour period of broth culture (Fig. 5.2). 
NIS activity was first detected late at 7 hours of incubation, at which time the bacteria were in 
late growth phase, the absorbance (OD600) was 1.5, and the viable count was 1.2 x 109 CFU/mL. 
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The activity continued to increase after stationary phase was attained at 10 hours, at which time 
the absorbance (OD600) was 2.0 and the viable count was 1.7 x 109 CFU/mL. 
 
Fig. 5.1. Enrichment of an NTHi inhibiting substance (NIS) in H. haemolyticus BW1 cell-free 
culture broth by ammonium sulfate precipitation. At 50 % saturation the NIS was partially 
extracted, but at least 60 % was required for full extraction. Ammonium sulfate solutions were 
incubated for 2 hours at 4°C, centrifuged, then precipitates resuspended in 1/20th volume of DPBS. 
Activity assessed by agar well diffusion assay with NTHi indicator strain NCTC 4560 (annular 
radius of clearing zones). 
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Fig. 5.2. Production of BW1-NIS in broth culture. The BW1-NIS activity was first measurable at an 
OD600 of 1.5 at 7 hours of incubation, and continued to increase until after stationary phase was 
attained at 10 hours. H. haemolyticus BW1 grown in sBHI broth at 37°C with 200 RPM agitation. 
Activity assessed by agar well diffusion assay against NTHi indicator strain NCTC 4560. Annular 
radius of clearing zone, mean +/- SEM, five independent experiments. 
The spectrum of activity of BW1-NIS was tested by agar well diffusion assay, with NTHi and 
other clinically relevant bacteria being the overlayed indicator strains in the assays. All of 102 
NTHi, 21 Hib, and 17 of 30 H. haemolyticus were inhibited by BW1-NIS. The H. haemolyticus 
strains BW1, ATCC 33390 and the other 11 isolates were not inhibited. No other bacteria were 
inhibited by BW1-NIS (Table 5.1). The complete spectrum of activity testing results for BW1-
NIS are shown in Appendix 2.  
  
  Chapter 5. Characteristics of a NIS 
59 
 
 
Table 5.1. Spectrum of activity of BW1-NIS. The activity of a NIS produced by H. haemolyticus 
BW1 was tested against listed organisms, in agar well diffusion assays. Complete results are in 
Appendix 2. 
Genus species, capsular 
serotype 
Origin No. inhibited/ 
No. tested (%) 
Haemophilus influenzae, NTHi NCTC 4560, NCTC 11315, isolates 102/102 (100) 
Haemophilus influenzae, b  ATCC 43163, isolates 21/21 (100) 
Haemophilus influenzae, c ATCC 9007 1/1 
Haemophilus haemolyticus  ATCC 33390, isolates 17/30 (57) 
Haemophilus parainfluenzae Isolates 0/2 
Acinetobacter baumanii  ATCC 17409 0/1 
Burkholderia cepacia  ATCC 25416 0/1 
Enterococcus faecalis  ATCC 29212, POW 1994 0/2 
Enterococcus faecicum Isolate 0/1 
Enterococcus gallinarum ATCC 49573 0/1 
Escherichia coli  NCTC 11560, ATCC 10418, DH5α 0/3 
Moraxella catarrhalis   ATCC 25238 0/1 
Neisseria lactamica  ATCC 23970 0/1 
Proteus vulgaris  ATCC 8427 0/1 
Pseudomonas aeruginosa  ATCC BAA-47 0/1 
Staphylococcus aureus ATCC 25923, 29213, 33591 0/3 
Staphylococcus epidermidis  ATCC 12228 0/1 
Streptococcus bovis  ATCC 35034 0/1 
Streptococcus pneumoniae  NCTC ARL 10582, ATCC 6305 0/2 
Streptococcus pyogenes  ATCC 19615 0/1 
 
In a comparison of the spectrum of activity of haemocin and BW1-NIS against the 30 H. 
haemolyticus isolates, the results were highly variable. Although a regression of clearing zones 
size showed a significant positive relationship overall (Fig. 5.3), they could be divided into 
four groups. Twelve isolates were inhibited by neither, 3 were inhibited by haemocin only, 4 
were inhibited by BW1-NIS only, and 11 were inhibited by both.  The complete spectrum of 
activity testing results are shown in Appendix 2. 
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Fig. 5.3. The inhibition of H. haemolyticus growth, by haemocin and BW1-NIS, are positively 
related. Using agar well diffusion assays, preparations of haemocin and BW1-NIS were tested 
against H. haemolyticus organisms (n = 30), and clearing zones measured. Markers at (0,0) and 
(0, 3) comprised of 12 and 2 isolates respectively. Complete results are in Appendix 2. 
The resistance of BW1-NIS to heating was assessed in three experiments of varying incubation 
temperature and time. In the first heating experiment, there was no reduction in activity 
following incubation of samples for 15 minutes in a heating block which was set to 
temperatures ranging from 40 to 100°C. In the second experiment, the blank attained 90°C after 
7 minutes of heating, and the activity was undiminished at 30 minutes, at 60 minutes and 120 
minutes (Fig. 5.4). For the third experiment, no activity was detectable after autoclaving. In 
testing of the resistance of BW1-NIS to inactivation by pH extremes, the activity was 
undiminished, when incubated at room temperature for 1 hour, at pH values from 1.6 to 9.7 
(Fig. 5.5). 
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Figure 5.4. Stability of BW1-NIS at 90°C. Activity assessed by agar well diffusion assay against 
NTHi indicator strain NCTC 4560, with annular radius of clearing zones shown.  
 
Figure 5.5. Stability BW1-NIS at pH extremes. A preparation of BW1-NIS was adjusted to varying 
pHs with HCl and NaOH, incubated for 1 hour at room temperature, then neutralized. Three 
replicates per treatment. Activity measured by agar well diffusion assay with NTHi indicator strain 
NCTC 4560 (annular radius of clearing zones).  
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The chemical composition of the active component in BW1-NIS was assessed, by treatment 
with proteases and a DNAse. After incubation overnight at 37°C, proteinase K reduced BW1-
NIS activity to levels that were undetectable, whereas trypsin treatment reduced the activity 
but it was still detectable. Treatment with DNAse I did not reduce the activity. 
The molecular size of BW1-NIS was determined using size exclusion chromatography. A 
10mL load of BW1-NIS was passed over a Superdex 200 column, and 69 x 4mL samples 
collected, with activity detected in fractions 33 to 41, with the peak of activity in fraction 37, 
at an elution volume of 222mL (Fig. 5.6). The molecular size of BW1-NIS was then predicted, 
with a globular protein molecular weight standard, to be approximately 32 kDa, under native 
conditions (Fig. 5.7). 
 
Fig. 5.6. Size exclusion chromatography of BW1-NIS. The peak of BW1-NIS activity occurs in the 
fraction with an elution volume of 222mL, between the volumes at which ovalbumin and 
myoglobin are eluted from the column. Activity assessed by well diffusion assay against NTHi 
indicator strain NCTC 4560 (annular radius of clearing zone). Molecular weight standards 
thyroglobulin (TG), γ-globulin (GG), ovalbumin (OA), myoglobin (MG). Vitamin B12 (B12) 
indicates buffer front. 
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Fig. 5.7. Estimation of molecular weight of BW1-NIS. A molecular weight of 32 kDa is calculated 
for BW1-NIS from the calibration curve of the size exclusion chromatography column, and from 
a BW1-NIS elution volume of 222mL. Molecular weight standards thyroglobulin (TG), γ-globulin 
(GG), ovalbumin (OA), myoglobin (MG).  
To assist in determining if BW1-NIS is haemocin, the gDNA of BW1 was tested for hmcA by 
real-time PCR.  Both BW1 and RHH122, the other NIS-producing H. haemolyticus isolate, 
were negative for hmcA.  
5.4 Discussion  
The objective of this study was to understand the production, activity and chemical 
characteristics of BW1-NIS. We were able to show that enrichment was achieved with an 
ammonium sulfate saturation of 60% or more, and activity was only detectable when the 
absorbance (OD600) of the culture broth was 1.5 or greater. BW1-NIS was resistant to 
inactivation by heat, pH extremes and DNAse I, but was degraded by proteinase K. Spectrum 
of activity testing showed that BW1-NIS was active against all tested NTHi, Hib, and some H. 
haemolyticus, but no bacteria from ten other clinically relevant genera. The molecular size of 
BW1-NIS was approximately 32 kDa, and BW1 gDNA was negative for the presence of hmcA. 
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We determined that ammonium sulfate concentrations of 60, 70 and 80% saturations were 
equally effective at enriching BW1-NIS (Fig. 5.1), and as result 70% saturation was used for 
all subsequent enrichment procedures. This working concentration differs from the 55% 
saturation we used for preparation of enriched cell-free culture broth in Chapter 4, a 
concentration which was chosen from the methods used for the discovery of haemocin 
(Venezia and Robertson, 1975). It is conceivable that re-screening our H. haemolyticus 
collection for NIS by enriching with 70% ammonium sulfate saturation may uncover other NIS 
producing isolates.  
For the characterisation of BW1-NIS, it is informative to compare it with haemocin. As was 
the case for haemocin (Venezia and Robertson, 1975), the activity in the culture broth 
(presumably related to amount of BW1-NIS present) increased rapidly during the late growth 
phase, with the increase slowing but continuing during stationary phase (Fig. 5.2). However, 
BW1-NIS required seven hours of culture and a population of approximately 1.2 x 109 CFU/mL 
to be first detectable, whereas haemocin was detectable after only 4 hours of growth, and a 
population of approximately 5 x 107 CFU/mL. This discrepancy may prove to be revealing of 
a difference in the specific activity or mechanism for induction of the production of the two 
substances. There were some similarities in the spectrum of activity of the two substances, with 
BW1-NIS inhibiting 100% of H. influenzae and 57% of H. haemolyticus (Table 5.1), and 
haemocin inhibiting 93% of NTHi and 75% of H. haemolyticus (Venezia et al., 1977). 
However, when haemocin and BW1-NIS were tested on a common set of H. haemolyticus 
isolates (n = 30), although a regression of the clearing zone annular radii produced a significant 
positive relationship (Fig. 5.3), 12 isolates were not inhibited by either substance, 4 isolates 
were inhibited by BW1-NIS only, and 3 were inhibited by only haemocin. Also, there were 
other clear differences in the spectrum of activity of the two substances: E. coli was inhibited 
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by haemocin (Streker et al., 1981; Venezia and Robertson, 1975; Venezia et al., 1977), but not 
by BW1-NIS (Table 5.1); Hib are immune to the effects of haemocin (Murley et al., 1997, 
1998) but were inhibited by BW1-NIS.  
Using size exclusion chromatography, we showed that BW1-NIS had an estimated molecular 
size corresponding to a monomeric protein with a molecular weight of 32 kDa (Fig. 5.6, 5.7). 
Consistent with this estimate, BW1-NIS was retained by a 10 kDa MWCO centrifugal filter 
and 3.5 kDa dialysis tubing. However, we could not distinguish from our data whether this 
represents the molecular size of a BW1-NIS polypeptide, or a homo- or hetero-oligomer 
assembly thereof. In this regard, we note that the molecular size of haemocin was initially 
estimated, by retention in membrane filters, to be between 50 and 100 kDa (Venezia and 
Robertson, 1975); the purified polypeptide in the denatured state was less than 14 kDa by SDS-
PAGE (Venezia et al., 1977); and the molecular size predicted for the mature processed 
polypeptide using the gene sequence is only 5.0 kDa (Murley et al., 1998). These differences 
between BW1-NIS and haemocin, together with our RTPCR results which showed that hmcA 
was absent from BW1, are consistent with the evidence first presented in chapter 4, which 
showed that BW1-NIS and haemocin are different substances.  
Previously, in Chapter 4, we suggested that the anti-NTHi activity of BW1-NIS is consistent 
with either a siderophore, quorum sensing molecule or bacteriocin. The results in this Chapter 
provide some information relevant to answering this question.  It appears unlikely that BW1-
NIS is a siderophore, as these are usually low molecular weight molecules, of 0.5 kDa to 1.5 
kDa (Hider and Kong, 2010), whereas BW1-NIS is approximately 30 kDa. The quorum sensing 
acyl homoserine lactone molecules, which are common to Gram-negative bacteria, appear as 
unlikely candidates, also due to their very small molecular size. The degradation of BW1-NIS 
activity by proteinase K suggests that it is a peptide, which is also not consistent with 
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siderophores or quorum sensing molecules. Bacteriocins are peptides, have narrow spectrum 
of activity, molecular weight between 1 and 70 kDA, and may be resistant to extremes of heat 
and pH (Yang et al., 2014), and as such are fully consistent with the known characteristics of 
BW1-NIS. Indeed, although differences have already between outlined above, BW1-NIS and 
haemocin, the bacteriocin produced by Hib, share many characteristics, including similar 
spectrum of activity, resistance to extremes of heat and pH, and susceptibility to proteases 
(Venezia and Robertson, 1975).. 
In conclusion we have shown that BW1-NIS is most likely a peptide, possibly a bacteriocin, 
with very specific activity against the closely related species H. influenzae and some H. 
haemolyticus. We suggest that strains of H. haemolyticus that produce BW1-NIS may be useful 
as probiotics, and that further studies of the structure and function of BW1-NIS are required. 
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Chapter 6.  
Purification and sequencing of the NIS produced by H. 
haemolyticus (Hh-NIS) 
Figure 6.1 “SDS-PAGE analysis and NIS activity in SEC separated BW1-NIS”, from this 
chapter, has been incorporated into the publication “An isolate of Haemophilus haemolyticus  
produces a bacteriocin-like substance that inhibits the growth of nontypeable Haemophilus 
influenzae” by Latham, R. D., Gell, D. A., Fairbairn, R. L., Lyons, A. B., Shukla, S. D., Cho, 
K. Y., . . . Tristram, S. G.’ which was published in the International Journal of Antimicrobial 
Agents in April 2017 (doi:10.1016/j.ijantimicag.2016.12.010).  
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6.1 Introduction 
In chapter 4, we showed that H. haemolyticus isolates BW1 and RHH122 produced a diffusible 
substance that inhibits the growth of H. influenzae under the assay conditions employed. In 
chapter 5, we characterised some of the chemical and physical properties of an NTHi inhibiting 
substance (NIS) made by BW1, showing that it had narrow spectrum activity against H. 
influenzae, and determined that it was likely to be a proteinaceous substance, possibly a 
bacteriocin, with molecular size of approximately 32 kDa. We now sought to continue this 
investigation, by describing the protein and gene sequences of the NIS produced by BW1 
(BW1-NIS), as well as the NIS produced by RHH122 (RHH122-NIS).  
In this Chapter, we used size exclusion (SEC) and reverse-phase high-performance liquid 
chromatography (RP-HPLC) to obtain highly purified BW1-NIS and RHH122-NIS. Tryptic 
fragments of these preparations were analysed by mass spectrometry, and peptide sequences 
identified by matching the molecular mass of trypsin digest fragments against a hypothetical 
trypsin digest of H. haemolyticus proteins, derived from published genome sequence data. The 
candidate gene for the NIS made by BW1 and RHH122 (Hh-NIS) was cloned into in E. coli, 
expressed and tested for activity. The prevalence and variability of the ORF for the Hh-NIS 
gene were determined in Genbank, as well as in our bacterial collection. The structure and 
function of the protein were predicted with structure homology modelling. 
6.2 Methods 
6.2.1 Growth Media 
For this chapter, media for growth of H. haemolyticus was filter sterilised tryptone soya broth 
(Oxoid, CM1065) supplemented with HTM supplement (Oxoid, SR0158) and Vitox (Oxoid, 
SR0090A) (sTSB).This media was used in preference to sBHI, as testing showed that it 
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supported growth of H. haemolyticus and production of NIS, as well as clearer resolution of 
on silver-stained protein bands on SDS-PAGE gels. 
6.2.2 Enrichment of cell-free culture broths 
Similar to Chapters 4 and 5, cell-free culture broth was enriched by ammonium sulfate 
precipitation (Chapter 2.7), but with the precipitate formed at 50% saturation discarded, and 
the subsequent precipitate formed at 70% saturation retained, and hereafter is referred to as the 
50-70% fraction. 
6.2.3 Increased-sensitivity agar well diffusion assay for NIS activity 
For the investigation of Hh-NIS production by gene-positive isolates, bacteria were grown in 
sTSB, then the 50-70% fraction of the cell-free culture broth dissolved in a volume of DPBS 
equal to 1/100th (cf. 1/20th) of the culture broth volume. 
6.2.4 Size exclusion chromatography  
For separation of samples by size exclusion chromatography, a Superose 12 HR 10/300 GL 
column (GE Healthcare Life Sciences, 17-5173-01), with a bed volume of 24mL was used.  
The buffer was 0.15M Na phosphate pH 7.0, which ran at a flow rate of 0.75mL/min, at 21°C. 
6.2.5 Reversed-Phase High-performance liquid chromatography  
Samples were separated with a reversed phase high-performance chromatography (RP-HPLC) 
column (Waters, C4), with 0.1% trifluoracetic acid (TFA) for gradient buffer A, and 
acetonitrile with 0.1% TFA for gradient buffer B. Fractions were collected manually. 
6.2.6 Mass spectrometry analysis and database search  
This was performed by R. Wilson. SDS-PAGE gel slices, which contained protein bands, , 
were prepared for mass spectrometry analysis by rinsing twice in 0.5L of water, incubation for 
10 minutes in a solution containing 50% acetonitrile and 0.05M ammonium bicarbonate, then 
for 5 minutes in 100% acetonitrile, and finally drying by evaporation. An in-gel tryptic digest 
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of the bands was performed as described previously (Wilson et al., 2008). Briefly, gel slices 
were rehydrated for 1 hr at 4°C in 20µL of digest buffer (40mM ammonium bicarbonate and 
10% acetonitrile) containing 20ng/µL proteomics-grade trypsin (Sigma). A further 20µL of 
digest buffer was added to the samples, before incubation overnight at 37°C. The supernatants 
were then removed, incubated for 1 hour at 4°C with 30µL of peptide extraction buffer (50% 
acetonitrile in 0.1% formic acid), sonicated for 10 minutes in a water bath, and then dried. The 
dried tryptic peptides were then reconstituted with 20µL of HPLC Buffer A (5% acetonitrile in 
0.2% formic acid) before analysis by nanoscale liquid chromatography coupled to tandem mass 
spectrometry (nano LC-MS/MS), using an LTQ-Orbitrap XL (ThermoFisher Scientistic). For 
nano LC-MS/MS, the tryptic peptides were first loaded at 0.05mL/min onto a C18 capillary 
trapping column (Peptide CapTrap, Michrom BioResources), which was controlled by a 
Separations Module (Waters, Alliance 2690). Peptides were then separated on an analytical C18 
nano-column (New Objective, PicoFrit, 10cm with 15µm i.d pulled tip), controlled by a pump 
(Thermofisher Scientific, Surveyor MS Pump Plus) running at a flow-rate of 200 nL/min, over 
a 4-step gradient of 100% Buffer A to 100% Buffer B (90% acetonitrile in 0.2% formic acid). 
The gradient steps were as follows: 0 – 10% B, 7.5 min; 10 – 25% B, 50 min; 25 – 55% B, 20 
min; 55 – 100% B, 5 min; then hold at 100% B, 15 min. The software used for control of the 
LTQ-Orbitrap XL was Xcalibur 2.0 (ThermoFisher Scientific), which was operated in data-
dependent acquisition mode, with survey scans acquired in the Orbitrap at a resolving power 
of 60,000. The MS/MS spectra, for the eight most intense ions from the FT survey scan, were 
concurrently acquired in the LTQ mass analyser. Charge state filtering was used for unassigned 
and singly-charged precursor ions which were not selected for fragmentation, as well as 
dynamic exclusion (repeat count 1, repeat duration 1 sec, exclusion list size 500). The 
fragmentation conditions used were: 35% normalized collision energy, 0.25 activation q, 30ms 
activation time, and a minimum ion selection intensity of 500 counts. For database searching, 
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the MS/MS .raw files generated by Xcalibur 2.0 were searched against the Haemophilus 
haemolyticus database, downloaded from NCBI on 30 September 2016. Semi-tryptic searches, 
using parent ion and fragment ion mass tolerances of 10 ppm and 0.5 Da, were performed using 
X!Tandem running in CPAS (Rauch et al., 2006). The probabilities of the protein and peptide 
matches were calculated (Nesvizhskii et al., 2003) using the Protein Prophet and Peptide Prophet 
algorithms. 
6.2.7 Cloning and expression 
A PCR product was made using BW1 gDNA as template, with primers QVVGN.F (5’-
ATTACATATGCAGGTAGTGGGAAATGTATCA-3’) and FGGTKN.R (5’-
TTATCTCGAGTTAATTTTTAGTACCGCCAAA-3’), which coded for the mature peptide 
without the signal peptide (Fig. 6.5). A truncated version was also made, using primers 
DSSIPN.F (5’- ATTACATATGGACAGTAGTATTCCTAATGAT-3’) and FGGTKN.R. The 
PCR amplicons were separately annealed into plasmid PET28A, which had been cut previously 
with restriction enzymes NdeI and XhoI, using T4 DNA ligase. E. coli DH5 alpha was 
transformed with this construct and clones were verified by Sanger sequencing. E. coli 
expression strain BL21 was transformed with the plasmids and a starter culture was grown 
overnight in LB with 24 µg/mL kanamycin antibiotic; the overnight culture was inoculated into 
a fresh culture (1 L LB with kanamycin), induced with 1 mM IPTG at an absorbance (OD600) 
of ~0.6, and grown for 4 hours at 37 °C. Cells were collected by centrifugation at 4,000 x g for 
10 minutes, and resuspended in buffer (0.3M NaCl, 0.025M sodium phosphate, 10 mM 
imidazole, pH 7.1) containing DTT (1 mM) and PMSF (0.2 mM), and lysed by sonication 
(Sonics 500-Watt probe sonicator). The insoluble fraction was removed by centrifugation 
(17,000 rpm, Sorvall SS34 rotor, 4 °C).  The expressed proteins were then purified by affinity 
chromatography with Nickel HTC agarose resin (Gold Biotechnology, R-202). 
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6.2.8 RTPCR and Sanger sequencing 
An alignment of genes from Genbank (Appendix 3) were used to design primers for RTPCR 
and Sanger sequencing. Primers OMPA-726F (5’-TGTAAGGTGTGAAATCCATTTATCG-
3’) and OMPA-851R (5’-GGCGTTGAGATATATGACAGTAG-3’), which annealed within 
the ORF, were used for SYBR Green RTPCR testing, and primers OMPA-spanF (5’-
AATCCAGTATTAGTTGTTGATGC-3”) and OMPA-spanR (5’-
CTTGGTTGTTTATTGTTAATGTAG-3’), annealing outside the ORF, were used for PCR 
amplification and Sanger sequencing.   
6.3 Results 
Size exclusion chromatography fractions of BW1-NIS and RHH122-NIS preparations were 
assessed for activity by agar well diffusion assay, and visualised by SDS PAGE. A band of ca. 
30 kDa was present in column fractions that retained NIS activity, from BW1 and RHH122, 
and was not present in the equivalent fractions from two non-producing strains, BW39 and 
BWOCT3 (Figure 6.1, SDS-PAGE analysis of SEC fractions, for producing strain BW1 and 
non-producing strain BW39 only).  
  
 Chapter 6. Purification and sequencing of Hh-NIS 
73 
 
 
 
Fig. 6.1. SDS-PAGE analysis and NIS activity in SEC separated BW1-NIS. Load fraction (L) and 
elution fractions (F1–F6) from SEC were separated on 10% Tris-tricine SDS-PAGE and stained 
with silver. Molecular weight size standards (M) are indicated, together with activity measured as 
clearing zone annular radius (mm). A 30-kDa polypeptide was evident in BW1 samples (solid 
arrow head), but not in fractions from non-NIS producing H. haemolyticus isolate BW39 (open 
arrow head). 
The RHH122 SEC fraction with the highest abundance of the 30-kDa band (not shown, 
comparable to Fig. 6.1, BW1, F5) was separated by RP-HPLC (Fig. 6.2). Then, with the 
acetonitrile removed by evaporation and lyophilisation, the RP-HPLC fractions were 
resuspended in DPBS, the NIS activity was measured by agar well diffusion assay, and 
molecular weight of separated products determined by SDS-PAGE. Only the fraction collected 
at 20.3-21.2 minutes had NIS activity (Fig. 6.3), and a ca. 30 kDa band (Fig. 6.4), which was 
excised and subject to in-gel trypsin digest, and the derived peptides analysed by mass 
spectrometry. 
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Fig 6.2. RP-HPLC separation of SEC purified RHH122-NIS. The peak at 20.6 minutes has NIS 
activity (Fig. 6.3) and a 30 kDa band on SDS-PAGE (Fig. 6.4). Red line is the gradient, black line 
is the UV. 
The resulting masses from mass spectrometry analysis were compared against hypothetical 
tryptic digests, of the predicted proteins in Genbank, derived from the whole genome 
sequencing bioprojects of 13 H. haemolyticus strains (M19107, M19501, M21127, M21621, 
M21639, HK386, CCUG 24149, CCUG 39154, CCUG 12834, 27P25, 1P26, 3P5, 11P18). The 
comparison revealed a match for a hypothetical protein (EGT80255), described as a putative 
OMPA-like protein, identified from an ORF (Hh-NIS, AFQN01000044.1) in H. haemolyticus 
strain M19107 (AFQN). This strain was a carriage isolate, not associated with disease, from a 
study of invasive H. haemolyticus (Jordan et al., 2011). The hypothetical protein included a 
signal peptide (Fig. 6.5, sequence in blue), predicted by SIGNALP 4.1 (Petersen et al., 2011), 
that would be cleaved off between amino acid residue 22 and 23, AQA-QV. The position of 
this signal peptide cleavage site was confirmed with the presence, in the mass spectrometry 
analysis, of the peptide QVVGNVSTDTNQTR (Fig 5.5. first tract of sequence in red, after 
signal peptide). With the same methods of purification and mass spectrometry analysis applied 
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to BW1-NIS, an identical result was obtained, and BW1-NIS and RHH-122 NIS were then 
referred to as “Hh-NIS”. 
 
Fig. 6.3. Activity in RP-HPLC fractions from SEC purified RHH122-NIS. Activity from agar well 
diffusion activity, with NTHi strain NCTC 4560 as indicator. 
 
Fig 6.4. SDS-PAGE analysis of RP-HPLC purified RHH122-NIS. Lane M, molecular weight marker 
(kDa). Other lanes, RP-HPLC fractions, elution times (minutes) as shown. 
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MSVINKTILAVVVCGVVSVAQAQVVGNVSTDTNQTRYIKIKAGEKDGKAGVEIYDSSIPNDP
AVLSKTANNKGQSFEKMAERADKWISHLTGVAKKDKNGVIVAKMNKMPNLTLIMPDHRGL
GRLSFKQVGNQDTYFGEWENVDAATSAAKNVSVYYAGSDPTKTLPSGKATYTVEGINKYG
NFNSRLMKGTFDVDFERASISGYLSKPNLSLSIESKIDKTNATFEGIAKAEGVIGKSEGRFYGA
KAEGLAGMATFASKPEYNTAFGGTKN 
Fig. 6.5. RHH122-NIS is EGT80255 from H. haemolyticus M19107. Blue is signal peptide. Red are 
hypothetical tryptic fragments with masses matching the RHH122-NIS tryptic fragment masses. 
Standard single letter amino acid code.  
For the ultimate verification that Hh-NIS was the active peptide, the Hh-NIS ORF, minus the 
signal peptide was cloned from BW1 into E. coli, expressed (Fig. 6.6, lane 5) and purified on 
Ni-affinity resin (Fig. 6.6, lane 7), followed by size exclusion chromatography (Fig. 6.7 ), then 
tested for activity. The resulting preparation had the same NIS activity as BW1-NIS and 
RHH122-NIS preparations (Fig. 6.8, 3-1), confirming that the mass spectrometry analysis had 
identified the correct protein. A recombinant truncated Hh-NIS, in which 32 residues were 
removed from the N-terminus, showed similar level of expression in E. coli (Fig. 6.6. lanes 4, 
6) and mobility on SEC (not shown), suggesting it was substantially folded, yet was inactive. 
(Fig 6.8, 2-1). This sample provides a control, showing that it is unlikely that the NIS activity 
arose from a contaminating E. coli protein.  
 Chapter 6. Purification and sequencing of Hh-NIS 
77 
 
 
Fig. 6.6. SDS-PAGE analysis of recombinant Hh-NIS expression and Ni-affinity purification. Lane 
1, molecular weight markers, same as Fig. 6.4; lane 2, clone 2-1 pre-induction lysate; lane 3, clone 
3-1 pre-induction lysate; lane 4, lysate from clone 2-1 induced with 1 mM IPTG for 3 hours at 
37°C; lane 5, lysate from clone 3-1 induced with 1 mM IPTG for 3 hours at 37°C; lane 6, clone 2-
1 eluted from Ni-affinity; lane 7, clone 3-1 eluted from Ni-affinity. 
 
Fig. 6.7.  SEC purification of recombinant Hh-NIS. Ni-affinity purified Hh-NIS from clone 3-1 was 
passed over a SEC column, and the 19 to 21.5 minute eluate was collected for activity testing (Fig. 
6.8).  
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Fig. 6.8. Activity of recombinant Hh-NIS. There was NIS activity in recombinant Hh-NIS made in E. 
coli with the Hh-NIS ORF minus the signal peptide (3-1). In a truncated version, with 32 residues 
missing from the N-terminus, there was no activity (2-1). Agar well diffusion assay with NTHi 
reference strain NCTC 4560 as indicator. 
Genes similar to the Hh-NIS ORF (AFQN01000044.1) were identified in whole genome 
sequencing projects in Genbank for H. haemolyticus, H. influenzae, and H. quentini using 
NCBI blastn. Out of the 13 H. haemolyticus bioprojects, including M19107, 6 strains (46%) 
had ORF sequences that were 75% to 100% similar to Hh-NIS (Table 6.1). This set of 6 strains 
included 2 isolates (M21639, M21227) which had been identified as invasive (Jordan et al., 
2011). Of the 126 H. influenzae bioprojects, 3 (2%) had genes that were 75% similar to the Hh-
NIS ORF. In the 3 H. quentini bioprojects, all 3 (100%) had ORF sequences that were 97% 
similar to the Hh-NIS ORF.  
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Table 6.1. Genbank whole genome sequencing projects with genes similar to the Hh-NIS ORF. 
Comparisons between Haemophilus spp. in Genbank, including 13 H. haemolyticus, 126 H. 
influenzae and 3 H. quentini, and the 816 bp Hh-NIS ORF (AFQN01000044.1).  
Species-strain (Genbank accession code) Similarity (%) 
Hh-M19107 (AFQN) 816/816 (100) 
Hh-11P18 (LCTK) 812/816 (99) 
Hq-C860 (MDJC) 795/816 (97) 
Hq-K068 (MDJB) 795/816 (97) 
Hq-MP1 (MCII) 795/816 (97) 
Hh-M21639 (AFQR) 795/816 (97) 
Hh-27P25 (LCTH) 605/805 (75) 
Hh-M21127 (AFQP) 605/805 (75) 
Hh-CCUG 24149 (LZDL) 600/804 (75) 
Hi-1104 (JFZM) 438/582 (75) 
Hi-584 (JFZL) 438/582 (75) 
Hi-411 (JFZK) 438/582 (75) 
  
In our collection of 100 H. haemolyticus isolates we examined, the prevalence and variability 
of the ORF for Hh1-NIS, and the NIS activity in the gene-positive isolates. Using primers 
annealing within the ORF, 15 (15%) of the isolates were positive for Hh-NIS by RTPCR, and 
using primers annealing outside of the ORF, 11 of these 15 (11% of total) could be amplified 
by PCR and then sequenced (Table 6.2). The other four that were positive in the RTPCR 
(BW36, L117, L152, L153) did not amplify in the second PCR (and so were not sequenced). 
The sequences from six isolates (BW1, RHH122, BW15, BW18, NF4, NF5) were identical to 
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the Hh-NIS ORF, and the other five (BW5, CF14, L19, NF6, NF11) were divergent (Table 6.2). 
Of the 156 NTHi isolates in our collection, none (0%) were positive by RTPCR for the presence 
of the Hh-NIS ORF. 
Expression of Hh-NIS by the RTPCR-positive isolates was assessed using an increased-
sensitivity agar well diffusive assay. The NIS activity was measured in 100-fold (cf. 20-fold) 
enriched solutions, and with solution concentrations equalised for the culture density (Table 
6.2). The isolates with ORF sequences identical to Hh-NIS, all showed evidence for Hh-NIS 
production, however production was higher in BW1 and RHH122 than any of the other isolates 
(Table 6.2). One isolate (NF6), with an ORF sequence divergent from M19107, showed signs 
of NIS activity, although at a lower level than the isolates with sequences identical to Hh-NIS. 
There was NIS activity produced by the isolates BW36, L152 and L153, which could not be 
sequenced, even though they were RTPCR-positive. 
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Table 6.2. Hh-NIS ORF prevalence and variability, and NIS activity, in our H. haemolyticus 
collection. The 100 H. haemolyticus isolates in our collection were tested for prevalence and 
variability of the Hh-NIS ORF (accession AFQN01000044.1) by RTPCR and sequencing, and for 
evidence of production of Hh-NIS by an increased-sensitivity agar well diffusion assay. Isolates 
for which no sequence similarity is available (NA), that did not amplify with the sequencing PCR, 
using primers annealing outside the ORF. NA, not available. * includes gaps. ND, not determined. 
Culture density, absorbance (OD 600nm). Activity, annular radius (mm).  
Isolate RTPCR Sequencing 
PCR 
Sequence 
similarity (%) 
Activity Activity, 
equalised for 
culture 
density  
BW1 + + 816/816 (100) 5.5 3.75 
BW5 + + 804/816 (99) 0 0 
BW15 + + 816/816 (100) 2 0 
BW18 + + 816/816 (100) 3 0 
BW36 + - NA 3 ND 
CF14 + + 783/816 (96) 0 0 
L19 + + 706/830* (85) 0 0 
L117 + - NA 0 0 
L152 + - NA 3 0 
L153 + - NA 3 0 
NF4 + + 816/816 (100) 2 0 
NF5 + + 816/816 (100) 3.5 2 
NF6 + + 783/816 (96) 1 0 
NF11 + + 785/816 (96) 0 0 
RHH122 + + 816/816 (100) 5.5 3.5 
 
 Chapter 6. Purification and sequencing of Hh-NIS 
82 
 
Using SWISS-MODEL for protein structure homology modelling (Biasini et al., 2014), HpuA 
from Kingella denitrificans (protein data bank accession 5ee4; crystallized in complex with 
human oxy-haemoglobin) was identified as the most similar template, and a model for Hh-NIS 
protein was generated (Fig. 6.9). The software indicated the presence of a beta barrel in the C-
terminal region of Hh-NIS with high confidence (Fig. 6.9, blue). Prediction for the N-terminal 
region was of low confidence (Fig. 6.9, red); and is the region corresponding to the part of 
HpuA that binds to haemoglobin (Wong et al., 2015). 
 
Fig. 6.9. Model structure of Hh-NIS. Generated by SWISS-MODEL, based on homology to HpuA 
from Kingella denitrificans, with cartoon view shown. Blue, high confidence; red, low confidence. 
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Protein structural homology modelling was also conducted on the translations of the Hh-NIS 
ORF, identified by the blastn algorithm in Genbank whole genome sequencing projects (Table 
6.1), as well as from the isolates in our collection (Table 6.2). As was the case for Hh-NIS in 
BW1, RHH122, and M19107, all structures were most similar to HpuA from Kingella 
denitrificans, and the structure of the beta-barrel (Fig. 6.9, blue) was consistently predicted, 
but there was variability in the N-terminal regions.  
6.4 Discussion  
In this study, the NTHi inhibiting substances (NIS) produced by BW1 and RHH122 were 
purified, and then with mass spectrometry analysis, shown to be EGT80255 (Hh-NIS), a 
hypothetical protein from an isolate of H. haemolyticus (M19107). Finally, a structure of Hh-
NIS was constructed, based on its homology with HpuA. 
The mature Hh-NIS peptide was 27 kDa (subsequent to cleavage of the signal peptide), similar 
but not identical to the 32 kDa predicted in Chapter 6, and the approximate 30 kDa observed 
on SDS-PAGE (Fig. 6.1, 6.4, 6.6). Although this small discrepancy may be within the normal 
limits of error expected for SEC, because elution time scales with the logarithm of the 
molecular weight, this consistent over-estimation of the molecular size, could also be a “gel 
shift” (Rath et al., 2009), which occurs in the presence of SDS, and causes protein shape as 
well as molecular size to contribute to electrophoretic mobility. 
The structural gene for Hh-NIS (Hh-NIS, accession AFQN01000044.1) was identified from a 
carriage isolate (M19107) in a study of the genomes of H. haemolyticus isolates causing disease 
(Jordan et al., 2011). Although the M19107 strain was not associated with pathogenicity, two 
invasive isolates (M21639, M21227) from the same study carried the gene, albeit with 75% 
similarity. Although noteworthy, the small number of isolates in that study - two carriage 
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isolates and three associated with disease - do not allow us to make any meaningful conclusions 
about the relationship between pathogenicity and presence of Hh-NIS. Indeed, the rarity of H. 
haemolyticus disease in humans will make challenging for any in vivo study of the association 
between Hh-NIS and pathogenicity. 
In an examination of our H. haemolyticus collection, six isolates (BW1, RHH122, BW15, 
BW18, NF4, NF5) had sequences identical to the Hh-NIS ORF, but their NIS activity was 
highly variable, with BW1 and RHH122 consistently higher producers. Even with correction 
for culture density (Table 6.2), these differences were apparent, and therefore appear to be due 
to different levels of expression. To gain an understanding of the control of expression of Hh-
NIS, an examination of the sequences in these six isolates upstream of the Hh-NIS ORF is 
suggested, as it is the likely position for a promotor. 
The above suggested differences in sequences upstream of the ORF, could also explain the 
results for the H. haemolyticus isolates BW36, L152 and L153. These three isolates were 
positive for NIS activity and presence of Hh-NIS ORF, by RTPCR of an internal fragment, but 
were not sequenced due to lack of amplification of the sequencing PCR. The primers for the 
sequencing PCR had been designed to anneal adjacent to the ORF, and it is conceivable that 
the ORF in these isolates was 100% similar to that of M19107, but variability in one or both of 
the primer binding sites adjacent to the ORF had caused the PCR failure To determine if this 
is the case, the ORF of these three isolates should be sequenced, initially with primers that 
anneal within the ORF. 
The prevalence of Hh-NIS in H. quentini, a rare cause of genitourinary tract infection (Horie et 
al., 2017) and neonatal bacteraemia (Hubbard et al., 2016), is higher than in other Haemophilus 
species. All three (100%) of the H. quentini Genbank genomes contained Hh-NIS, whereas in 
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H. haemolyticus, the rate of prevalence was 46% in the published genomes, and 15% in our 
collection by RTPCR. In H. influenzae, only 2% of published, and 0% in our collection were 
carrying Hh-NIS. Although the number of H. quentini strains examined was small, they may 
reflect the larger population, as this species is genetically relatively homogenous (Bruant et al., 
2003; Quentin et al., 1990, 1993). However, we do not expect this high prevalence of Hh-NIS 
in H. quentini to be significant for the overall aim of our project, the assessment of the potential 
of H. haemolyticus to inhibit the growth of NTHi, as H. quentini is a resident of the genito-
urinary tract (Glover et al., 2011), and H. haemolyticus and H. influenzae are resident of the 
respiratory tract, and so are unlikely to be in a competitive situation.  
Although the mass spectrometry analysis described Hh-NIS as a putative OMPA-like protein, 
an experimentally verified function was provided by structural homology modelling. Using 
SWISS-PROT, amino acid sequences were compared against proteins with known function 
and experimentally determined tertiary structure, and the Hh-NIS protein was identified as 
most similar to HpuA from Kingella denitrificans and Neisseria gonohorreae. HpuA is an outer 
membrane protein reported to be required for the removal of haemoglobin from haemoglobin-
haptoglobin complexes, and as such would appear to be of interest to us, as the haem 
requirement of H. influenzae and H. haemolyticus can be provided by haemoglobin. However, 
this apparent functional similarity is likely misleading, as HpuA binds only the globin protein 
of the haemoglobin complex (Wong et al., 2015), and the predicted structure of the ligand-
binding region (Fig. 6.9, red colour) is of low confidence.  
In this Chapter we determined the sequence of the Hh-NIS protein and the Hh-NIS ORF, and 
showed that recombinant Hh-NIS was active. Although some structural similarities to HpuA 
were shown, the mechanism for the inhibitory activity of Hh-NIS is not yet unknown, and will 
be the subject of the final experimental chapter of this thesis. 
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7.1 Introduction 
In Chapter 6, BW1-NIS and RHH122-NIS were demonstrated to be a protein (Hh-NIS, 
accession EGT80255) in Genbank, deduced from a whole genome sequencing project (AFQN) 
of H. haemolyticus carriage isolate M19107. Recombinant E. coli, with the ORF (Hh-NIS) 
cloned in, expressed recombinant Hh-NIS. In silico structural modelling of Hh-NIS revealed 
similarity to HpuA, a haemoglobin binding protein present in some haem-auxotrophic 
pathogenic bacteria, including Neisseria meningitidis, N. gonohorreae and Kingella 
denitrificans. We now seek to understand the mechanism by which Hh-NIS inhibits NTHi 
growth. 
In this Chapter, working with purified recombinant Hh-NIS, the absorbance spectrum was 
assessed, and highly purified fractions prepared. The NIS activity and minimum inhibitory 
concentration of the fractions were determined, and the effect of haemin supplementation on 
the activity of BW1-NIS and recombinant Hh-NIS were investigated.  
7.2 Methods 
7.2.1 Highly purified Hh-NIS 
Recombinant Hh-NIS was purified by D. Gell. Briefly, Hh-NIS was expressed in E. coli and 
purified by Ni affinity chromatography, as described previously (Chapter 6.2.7). The 6-His tag 
was then removed by protease cleavage at an engineered thrombin site, and the tag was 
removed on Ni-affinity. The Hh-NIS fraction was then separated by high-performance cation 
exchange (UnoS1, Biorad). It was noted that two distinct fractions containing Hh-NIS (F16 
and F17) eluted from the cation exchange column (Fig. 7.1). Wavelength scans (Fig. 7.2) 
revealed that, although F16 and F17 had similar absorbance at 280 nm, indicating similar 
protein concentrations (supported by SDS-PAGE, Fig. 7.3), F16 had strong absorbance at 414 
nm, 541 nm and 576 nm, suggesting that it contained a bound cofactor. The cofactor occupancy 
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in F16 was assumed to be 100%, hence this fraction was referred to as the holoprotein. A 
second cation exchange step was performed on F17, and was successful in removing most of 
the remaining contaminating holoprotein, thus yielding an apoprotein fraction. The cofactor 
occupancy of the apoprotein fraction was estimated, based on a comparison of the ratio of 
absorbances at 415 nm and 280 nm. The A415:A280 for the apoprotein fraction was 0.19, and 
2.5 for the holoprotein fraction, and as 0.19/2.5 is ~ 0.08, the cofactor occupancy in the 
apoprotein fraction was estimated to be 8%. 
 
Fig. 7.1. Cation exchange chromatographic separation of recombinant Hh-NIS. Purified 
recombinant Hh-NIS was separated on a UnoS1 column, and two distinct fractions, F16 (holo) and 
F17 (apo) were collected. Data provided by D. Gell. 
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Fig. 7.2. Wavelength scan of Hh-NIS fractions eluted from cation exchange chromatography. 
When normalized to the 280 nm protein absorbance peak, the 414 nm, 541nm and 576 nm 
absorbance peaks were more abundant in F16 (holo, red line) than F17 (apo, blue line) fraction. 
Data provided by D. Gell. 
 
Fig. 7.3. SDS-PAGE of cation exchange fractions of recombinant Hh-NIS. Fractions 16 (F16, red 
oval) and 17 (F17, blue oval; see Fig. 2) contained predominantly the 27 kDa Hh-NIS protein. 
Protein size standards (M) and load material, from Ni-affinity step, (L) are also shown. Coomassie 
blue staining. Data provided by D. Gell. 
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7.2.2 Minimum inhibitory concentration of recombinant Hh-NIS 
The minimum inhibitory concentration (MIC) of apoprotein and holoprotein preparations of 
Hh-NIS preparations was tested against NTHi. The dilutions were in 10-fold steps, and ranged 
from 0.00017µM to 1.7µM (holoprotein) and 0.0001µM to 1.0µM (apoprotein). Set up in 96-
well tissue culture plates, each well contained 100µL sTSB and 100µL of the Hh-NIS 
preparation diluted in DPBS. Wells were inoculated to an absorbance of 0.05 (OD600) with 5µL 
of NTHi strain NCTC 4560 or NCTC 11315, which had been grown for 9 hours on CA, then 
suspended in DPBS. Growth was assessed by measurement of absorbance (OD600) with a plate 
reader, after incubation for 5.5 hours at 35°C with 5% CO2. BW1 was included in the testing 
as a negative control 
7.2.3 Haemin solution 
A stock solution of 2000 µg/mL haemin (Sigma, 51280) was prepared in 0.1M NaOH, and 
stored in single-use aliquots at -20°C. 
7.2.4 Haemin requirements for growth 
The impact of haemin concentration on growth of BW1 and NTHi strain NCTC 4560 was 
assessed using broth culture in 96-well tissue culture plates. The haemin concentrations tested 
were from 40 µg/mL to 0.16 µg/mL, in two-fold steps. The media in each well was 200µL of 
TSB supplemented with Vitox (Oxoid, SR0090), NAD at 10µg/mL, and 4µL of haemin diluted 
in 0.1M NaOH. Each well was inoculated to an absorbance of approximately 0.05 (OD600), 
with 5µL of either BW1 or NCTC 4560 suspension in DPBS, prepared from a 14-hour culture 
on chocolate agar. Growth was assessed by measurement of absorbance (OD600) with a plate 
reader. 
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7.2.5 Effect of haemin on BW1-NIS activity in solid culture 
Haemin was serially diluted in 0.1M NaOH, then 5µL combined with 20µL of a BW1-NIS 
preparation (Chapter 6.2.1, 6.2.2), with the resulting mixtures containing 40 µg/mL to 0.16 
µg/mL haemin, in 2-fold steps. The NIS activity of the mixtures were tested in agar well 
diffusion assays, with NTHi strains NCTC 4560 and NCTC 11315 as indicators. 
7.2.6 Effect of recombinant Hh-NIS in haemin-limited broth culture 
The effect of recombinant Hh-NIS on growth of NTHi strain NCTC 4560 and BW1 was 
assessed in haemin-limited broth culture in 96-well plates. Haemin concentrations used were 
0.625 µg/mL and 5 µg/mL, with 7.7µM of recombinant Hh-NIS holoprotein, which was 
equimolar to 5 µg/mL haemin. Each well contained 200µL of TSB supplemented with Vitox. 
NAD at 10µg/mL, 4µL of haemin diluted in 0.1M NaOH, and 5µL of the holoprotein 
preparation. Each well was inoculated to an absorbance of approximately 0.05 (OD600), with 
5µL of a DPBS suspension of either BW1 or NCTC 4560, prepared from a 14-hour culture on 
chocolate agar. Growth was assessed by measurement of absorbance (OD600) with a plate 
reader. 
7.3 Results 
The recombinant Hh-NIS preparation was red-brown coloured, which led us to determine the 
visible absorbance spectrum. There was a strong absorbance peak at ~414 nm, which was 
reminiscent of the Soret band seen in metalloporphyrins and haemoproteins. To investigate this 
further, the absorbance spectrum of Hh-NIS was compared with spectra of the haemoprotein, 
haemoglobin (Hb). The wavelength scan of purified recombinant Hh-NIS identified a strong 
absorption peak at 414 nm, and two lesser peaks at 541 nm and 576 nm, and was highly similar 
to the spectrum of oxy-haemoglobin (Fig. 7.4), which contains haem with an Fe(II) metal, and 
an O2 ligand. Met-haemoglobin, in which the haem is in the Fe(III) oxidation state, had only a 
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405 nm peak in this region. As such, Hh-NIS was thought to contain haem in which the iron 
was in the Fe (II) state and potentially also had an O2 ligand bound. This result, which showed 
that Hh-NIS binds haem, led us to speculate that haem has a role in the activity of Hh-NIS, 
which was intriguing, as H. haemolyticus and H. influenzae are haem-auxotrophic. 
 
Fig. 7.4. Wavelength scan of recombinant Hh-NIS. The absorbance spectrum of purified recombinant 
Hh-NIS contained 414 nm, 541 nm, and 576 nm peaks that were similar to absorption peaks in a 
spectrum of oxy-haemoglobin (HbO2; spectrum provided by D. Gell), but not present in met-
haemoglobin (metHb; spectrum provided by D. Gell). 
The NIS activity of the apo and holo fractions of recombinant Hh-NIS was investigated. When 
tested by agar well diffusion assay, apoprotein concentrations between 2.6µM and 21µM (neat 
preparation) produced measurable clearing zones (Fig. 7.5), and for the holoprotein, zones were 
measurable between 4.5µM and 36µM (neat preparation). The relative activity of the 
apoprotein fraction was 1.7-times that of the holoprotein fraction, based on the concentrations 
required to produce clearing zones of annular radius 3.5, 4, and 4.5mm (Fig 7.5, 7.6). However, 
as this is a relatively small difference in activity, and it might also have arisen from difficulties 
experienced in accurately measuring the concentration of the holoprotein, we considered the 
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activity of both fractions to be equivalent, and that haem was not a cofactor which activated an 
enzymes, but that it had some other role.  
 
Fig. 7.5. Activity of apo and holo recombinant Hh-NIS fractions. When separated with UnoS1 cation 
exchange column, and tested with an agar well diffusion assay, there was activity in both F16 
(holo) and F17 (apo) fractions. 
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Fig 7.6. NIS activity in apo and holo fractions from recombinant Hh-NIS. The apo fraction (blue 
line) had consistently more activity than the holo fraction (red line). 
The minimum inhibitory concentration of the apo and holo fractions was investigated in 
haemin-replete broth culture. The holoprotein fraction of recombinant Hh-NIS did not inhibit 
the growth of NTHi strains NCTC 4560 and NCTC 11315 at any concentration up to 1.7µM 
(Fig. 7.7). For the apoprotein fraction, there was no inhibition of NTHi strain NCTC 4560 at 
any concentration, up to 1.0µM (Fig. 7.8). Although the growth of NTHi strain NCTC 11315 
was reduced by 30% (from 0.23 to 0.16, OD600) at the lowest apoprotein concentration 
(0.0001µM), there was no further reduction with increasing concentration. Accordingly, we 
assumed there to be an absence of inhibitory activity in the apoprotein and the holoprotein 
fractions, in the haemin-replete conditions of the assay. We then endeavoured to determine the 
activity of Hh-NIS in haemin-limited conditions. 
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Fig 7.7. Minimum inhibitory concentration (MIC) testing, holo fraction. There was no apparent 
inhibition of growth of NTHi strains NCTC 4560 (blue), NCTC 11315 (orange) and BW1 (grey) 
by the holo fraction of recombinant Hh-NIS. Broth is sTSB, which contains 15 µg/mL haemin. 
 
Fig 7.8. MIC testing, apo fraction. There was no apparent inhibition of growth of NTHi strains NCTC 
4560 (blue) and NCTC 11315 (orange), and BW1 (grey) by the apoprotein of recombinant Hh-
NIS. Broth is sTSB, which contains 15 µg/mL haemin.  
For the determination of haemin-limited conditions, the haemin requirements for the growth of 
BW1 and NTHi strain NCTC 4560 were investigated, and BW1 was found to have a far higher 
requirement. The maximum absorbance (OD600) for NCTC 4560 (0.28) was attained in only 
0.625 µg/mL haemin (Fig. 7.9), whereas the maximum absorbance for BW1 (0.37) required a 
25-fold higher concentration (40 µg/mL, Fig. 7.10). 
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Fig 7.9. Growth response of NTHi to haemin. At 19 hours (grey), the growth of NCTC 4560 was 
reduced only when the haemin concentrations was 0.31 µg/mL or less. 8 hours (blue), 12 hours 
(orange). Broth culture in TSB supplemented with Vitox, NAD and variable haemin concentration. 
Initial absorbance ∼0.05 (OD600). 
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Fig 7.10. Growth response of BW1 to haemin. A haemin concentration of at least 0.31 µg/mL was 
required for any growth of BW1, and greater concentrations incrementally increased growth. 8 
hours (blue), 12 hours (orange), 19 hours (grey). Broth culture in TSB supplemented with vitox, 
NAD and variable haemin concentration. Initial absorbance ∼0.05 (OD600).  
The effect of haemin concentration on Hh-NIS activity was then examined, in haemin-limited 
conditions. Haemin was serially diluted and mixed with BW1-NIS, then activity against NTHi 
strains NCTC 4560 and NCTC 11315 assessed by agar well diffusion assay. With haemin 
concentrations of 40 µg/mL and 20 µg/mL, the activity of BW1-NIS was completely 
neutralised (Fig. 7.11, 7.12), and, even increased the size of the surrounding colonies (Fig. 
7.11, only NCTC 11315 shown). At 10 µg/mL there was slight inhibitory activity, and with 
haemin concentrations ranging from 2.5 µg/mL to 0.16 µg/mL, inhibitory activity was clearly 
observed and unchanged. With the results from agar well diffusion assay showing that a 
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reduced haemin concentration was critical, the activity of Hh-NIS in broth could then be 
investigated. 
 
Fig 7.11. Addition of haemin neutralises the inhibitory activity of BW1-NIS. Agar well diffusion 
assay with wells containing BW1-NIS mixed with haemin at variable concentrations (values 
shown, µg/mL). Positive control (+) contains BW1-NIS only. Negative control (-) contains DPBS. 
Indicator is NTHi strain NCTC 11315. 
 
Fig 7.12. Addition of haemin neutralises the inhibitory activity of BW1-NIS. Agar well diffusion 
assay, with NCTC 4560 (blue) and NCTC 11315 (orange) as indicators. 
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The effect of Hh-NIS on NTHi and BW1 was investigated in broth, using haemin-limited 
conditions. With haemin at 0.625 µg/mL and 5 µg/mL (7.7µM), addition of 7.7µM of the 
holoprotein fraction of recombinant Hh-NIS resulted in reduced growth of NCTC 4560 (Fig. 
7.13) and increased growth of BW1 (Fig. 7.14), with the effect more obvious at the lower 
haemin concentration (Fig 7.13, 7.14, blue lines). Although preferable to similarly examine the 
apoprotein fraction, only the holoprotein fraction was available at the time of testing. 
 
Fig 7.13. In haemin-limited broth culture, the holo fraction of recombinant Hh-NIS reduced the 
growth of NTHi. With haemin at 5 µg/mL (red) and 0.625 µg/mL (blue), the addition of the Hh-
NIS preparation (broken line) reduced the growth of NTHi strain NCTC 4560, compared to the 
condition with no Hh-NIS (solid line). The base media was TSB supplemented with Vitox and 
NAD. 
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Fig 7.14. In haemin-limited broth culture, the holo fraction of recombinant Hh-NIS increased the 
growth of BW1. With haemin at 5 µg/mL (red) and 0.625 µg/mL (blue), the addition of the Hh-
NIS (broken line) increased the growth of H. haemolyticus isolate BW1, compared to the condition 
with no Hh-NIS (solid line). The base media was TSB supplemented with vitox and NAD. 
7.1 Discussion 
Together, the evidence we have fit a model for the mechanism of action of Hh-NIS, as follows: 
a minority of isolates of H. haemolyticus secrete Hh-NIS, which is a haemophore that binds 
haem and makes it available for use by H. haemolyticus isolates which produce Hh-NIS, but 
unavailable for use by NTHi. 
The  recombinant Hh-NIS was separated into holoprotein and apoprotein fractions, which were 
similar in activity. This was an unexpected result, as the holoprotein was 13-times more 
abundant in haem, and haem is typically a co-factor. This suggests that haem is not a co-factor 
which makes the apoprotein active, but that it has a different role.  
In the haemin-replete broth culture, the holoprotein and apoprotein fractions of recombinant 
Hh-NIS were not inhibitory to the growth of NTHi (Fig. 7.7, 7. 8). Possibly this result was due 
to the concentrations of the Hh-NIS preparations that were used. In the broth, because of limited 
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material availability, the highest concentrations which could be achieved were 1.0µM 
(apoprotein) and 1.7µM (holoprotein), both less than required to produce clearing zone in the 
agar well diffusion assay (Fig. 7.6). A repeat of this experiment, but with much higher 
concentrations of the apo and holo fractions, would help to test our model for the mechanism 
of activity of Hh-NIS. 
The effect of haemin addition to wells in an agar well diffusion assay was to neutralise the 
activity of Hh-NIS (Fig. 7.11). This result explained idiosyncrasies encountered in the 
development of the agar well diffusion assay, whereby reliable formation of clearing zones 
required the growth media to be at half-strength and aged several days, and the zone sizes also 
increased with the age of the media. With growth media at half-strength, the haemin will also 
be at half-strength, which will promote the formation of clearing zones, and with extended 
storage, the zone sizes increase because haemin is unstable in aqueous solution. 
The final evidence we had for describing the mechanism of action of Hh-NIS, is that in haemin-
limited broth culture, the holoprotein inhibited the growth of NTHi, and promoted the growth 
of BW1 (Fig. 7.13, 7.14). Although the inhibition of NTHi confirmed the results in agar well 
diffusion assay, the promotion of BW1 growth was informative for the development of our 
model, as we had not observed this previously.  
For the overall aim of this project, the prevalence of haem acquisition genes in NTHi has been 
linked with their pathogenic potential, which could have implications for the usefulness of Hh-
NIS-containing H. haemolyticus isolates as probiotics. In a study of the relationship between 
pathogenicity and haem-acquisition genes, the prevalence of hxuA, hxuB, hxuC, hemR, and hup 
in NTHi, was shown to be much higher than in H. haemolyticus  (Hariadi et al., 2015). Also in 
the same study, the prevalence of hxuA, hxuB, hxuC, and hemR was higher in NTHi isolates 
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from middle-ear acute otitis media samples, than in NTHi from throats swabs of healthy 
children. These results highlight the possibility that Hh-NIS may be a virulence factor for H. 
haemolyticus, which is also a rare cause of invasive disease in the immunocompromised. We 
suggest that a study of these haem acquisition genes, including Hh-NIS, in invasive, non-
invasive, and Hh-NIS producing isolates of H. haemolyticus would be informative with regards 
to an understanding of the virulence factors of invasive strains of H. haemolyticus, and the role 
of Hh-NIS. A comparison with haemophores of other pathogens may also be informative with 
regards to the pathogenic potential of Hh-NIS producing H. haemolyticus.  
A haemophore with functional similarities to Hh-NIS, exists in other opportunistic pathogens, 
but not H. influenzae, H. haemolyticus or other human-obligate pathogens. Serratia 
marcescens, Pseudomonas aeruginosa and Yersinia pestis secrete HasA, which binds haem 
and  delivers it to the outer-membrane receptor, HasR, for transport across the outer membrane 
(Ghigo et al., 1997; Letoffe et al., 1994; Létoffé et al., 1998; Rossi et al., 2001). Like Hh-NIS, 
HasA binds free haem (Létoffé et al., 1999; Yukl et al., 2010), which differs markedly from 
the HxuA haemophore of  H. influenzae, that binds to the haemopexin-haem complex, resulting 
in the release of the haem (Fournier et al., 2011; Hanson et al., 1992), and is associated with 
pathogenicity (Hariadi et al., 2015; Morton et al., 2007). As such, although Hh-NIS is a 
haemophore, we do not expect that it will be a virulence factor. 
In conclusion, Hh-NIS appears to be a haemophore, secreted by some isolates of H. 
haemolyticus, and binds haem into a form which is available to the same H. haemolyticus 
isolates, but is then no longer available to NTHi, resulting in inhibition of the growth of NTHi, 
but only under haem-limited conditions. Also, although Hh-NIS does appear to be a 
haemophore, we do not expect that it is a virulence factor, as it has similarities with HasA, 
which is not associated with pathogenicity. 
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The overall aim of this PhD project was to investigate the potential of H. haemolyticus as a 
respiratory tract probiotic against NTHi infection, with a focus on secreted NTHi inhibiting 
substances (NIS). A protein with NIS activity (Hh-NIS, accession EGT80255), produced by 
H. haemolyticus isolates BW1 and RHH122, was identified by comparison to a whole genome 
sequence of H. haemolyticus strain M19107, using mass spectrometry analysis. Hh-NIS was 
shown to inhibit the growth of NTHi, as well as promote the growth of BW1, in haem-limited 
conditions. A proposed mechanism for the activity of Hh-NIS was given, whereby Hh-NIS is 
a haemophore that binds haem into a form available for use by H. haemolyticus isolates which 
produce Hh-NIS, but is unavailable for use by NTHi. 
Initially (Chapter 3), SYBR Green RTPCR assays were developed for the identification of H. 
haemolyticus and H. influenzae, then used on a collection of isolates. At the time of their 
publication (Latham et al., 2015), these were the only RTPCR assays we were aware of which 
positively identified H. haemolyticus. SYBR Green was chosen over hydrolysis probes, as 
these assays are less costly and more readily available. However, subsequently there has been 
continued interest in H. haemolyticus and its interaction with NTHi (de Gier et al., 2015; 
Pickering et al., 2016), and there are alternative RTPCR assays for H. haemolyticus 
identification, which utilise hydrolysis probes, and target hypD (Price et al., 2017) or purT  (Hu 
et al., 2016). However, our assays, which target sodC and hpd, are still the only SYBR Green 
RTPCR method for H. haemolyticus identification we are aware of, apart from a PCR-high-
resolution melt method (Pickering et al., 2014) that we found unreliable in our laboratory. 
For Chapter 4, H. haemolyticus isolates were screened for phenotypic inhibition of NTHi, and 
the isolates BW1 and RHH122 were identified as consistent producers of a diffusible substance 
that inhibited NTHi. To describe what we now understand to be the activity of a haemophore, 
the term “NTHi inhibiting substance” (NIS) was introduced. In a publication about the same 
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protein (Latham et al., 2017) the term “bacteriocin-like substance” was also used. Most 
commonly, inhibitory substances, such as bacteriocins and antibiotics, exert their activity 
directly upon organisms. However, as we now understand this inhibitory activity is due to H. 
haemolyticus producing a substance which deprives NTHi of a commonly required nutrient 
(haem), the term “inhibitory substance” is likely to be misleading. As a result, we suggest that 
future publications should avoid referring to this protein as an “inhibitory substance”, 
“bacteriocin-like substance” or similar, even though the term has been used for consistency 
throughout this thesis.  
In Chapter 6, the amount of Hh-NIS that could be recovered from broth cultures of Hh-NIS-
positive isolates was highly variable. This was the case even for the six isolates with Hh-NIS 
ORF sequences identical to M19107, with BW1 and RHH122 producing more NIS activity 
than any, even when adjusted for cell density. Clearly, there are differences among the isolates 
in how the Hh-NIS is being produced, and as we are suggesting that H. haemolyticus isolates 
which secrete Hh-NIS have a competitive advantage against NTHi, elucidation of the control 
of Hh-NIS production and secretion is desirable.  
Structural homology modelling of Hh-NIS, in Chapter 6, showed it was most closely related to 
haemoglobin-haptoglobin utilisation protein A (HpuA) in Neisseria spp. and Kingella spp. 
Control of HpuA expression at the translational level has been demonstrated in N. gonohorreae, 
with insertional mutations in a poly-G tract in the ORF causing frame shifts, and on/off phase 
variability (Chen et al., 1998). However, this mechanism is not consistent with the expression 
variability or the homogeneity of the ORF sequences in the six H. haemolyticus isolates. 
Therefore, we suggest that control of expression at the transcription level is more likely, and 
that initially the sequences adjacent to the Hh-NIS ORF should be investigated, as it is the likely 
location of a promotor or other genes in an operon which influence Hh-NIS production and 
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secretion. Later, investigations of the involvement of other loci may be required, as the 
mechanisms which govern the concentration of Hh-NIS in the surrounding environment may 
not be fully under the control of an Hh-NIS operon. 
In Chapter 7, the possibility that Hh-NIS is a virulence factor of H. haemolyticus was discussed, 
but then considered unlikely, due to its apparent similarity to HasA, and dissimilarity with 
HxuA. Nevertheless, as we are suggesting the deliberate introduction into humans of H. 
haemolyticus strains which produce Hh-NIS, we advise caution, considering the Hh-NIS ORF 
was present in two of three invasive H. haemolyticus isolates, and all of the three genome 
sequences of H. quentini. As a result, prior to human trials, we recommend completion of the 
study of haem-acquisition genes in H. haemolyticus that was suggested in Chapter 7, as well 
as in vivo testing of the pathogenicity of isolates with and without Hh-NIS. 
Optimally, to understand the significance of a gene, knockout mutants are made and tested in 
biologically relevant conditions, as described in the molecular Koch’s postulates (Falkow, 
1988) for the determination of genes as virulence factors. Due to the constraints of the project, 
and as a substitute for an over-expression or gene knock-in experiment, purified Hh-NIS 
preparations were added to broth cultures of BW1 and NTHi, the results of which showed the 
Hh-NIS inhibited NTHi and promoted BW1 growth, but only in haemin-limited conditions. 
Although these experiments were informative, they do not substitute for studies with knockout 
and knock-in mutants, which isolate the effects of the Hh-NIS. As a result, we suggest that for 
any further investigation of the biological significance of Hh-NIS, the priority is to make 
knockout and knock-in mutants, and test them in conditions which mimic those present in the 
host.  
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On a more fundamental level, in this project we have made the initial discovery of a protein 
made by H. haemolyticus, which appears to be a haemophore, but that has some structural 
similarities to HpuA, a haemoglobin receptor of Neisseria spp. and Kingella spp. However, 
unlike HpuA, there are still many discoveries about Hh-NIS that are yet to be made, and which 
provide future research directions; tertiary and quaternary structure, manufacture and release 
from the bacterial cell, interacts with any haem-protein complexes, the strength and location of 
the haem, the involvement of any cell-surface receptors, and translocation of the bound ligand 
into cell. 
Finally, and with regards to the overall aim of this project, we have discovered H. haemolyticus 
isolates which were inhibitory to the growth of NTHi in vitro. This discovery provides evidence 
that microbial interference may be a viable mechanism for the inhibition of NTHi colonisation 
of the upper respiratory tract, and furthermore, that H. haemolyticus strains expressing Hh-NIS 
may be suitable as probiotics in this application. Accordingly, in the absence of an effective 
vaccine for the control of NTHi, for the development of a microbial interference approach, we 
recommend in vivo trials in humans. However, as haem-acquisition genes are associated with 
pathogenicity, in these trials a cautionary approach is advised.
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Appendix 1. 
NTHi tested for production of NIS.  NTHi indicator strains were NCTC 11315 and NCTC. 
Testing by agar well diffusion assay, with enriched cell-free culture broths. No isolates 
produced a NIS. 
CF28A M19 RHH50 
CF29 M21 RHH51 
CF31 M27 RHH53 
CF34 NF3 RHH54 
CF48 NF30 RHH55 
Ci11 NF37 RHH56 
Ci2 NF38 RHH60 
Ci29 NF7 RHH62 
Ci3 RHH1 RHH64 
Ci30 RHH12 RHH66 
Ci34 RHH14 RHH68 
Ci37 RHH15 RHH7 
Ci5 RHH17 RHH73 
Ci51 RHH19 RHH74 
Ci8 RHH20 RHH8 
Ci9 RHH21 RHH80 
H62 RHH22 RHH81 
L1 RHH28 RHH82 
L10 RHH29 RHH83 
L13 RHH3 RHH84 
L139 RHH31 RHH85 
L143 RHH32 RHH88 
L146 RHH34 RHH89 
L15 RHH35 RHH9 
L21 RHH36 RHH90 
L24 RHH37 ATCC 49766 
L26 RHH38 NCTC 4560 
L267 RHH39 NCTC 11315 
L27 RHH4  
L35 RHH41A  
L44 RHH41B  
L60 RHH42  
L76 RHH43  
L79 RHH44  
M03 RHH46 
 
M07 RHH47 
 
M11 RHH48 
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Appendix 2. 
Susceptibility to BW1-NIS and haemocin. Isolates/strains used as indicators in agar well 
diffusion assay. + susceptible, - not susceptible. 
Strain Species BW1-NIS Haemocin 
 
Strain Species BW1-NIS Haemocin 
ATCC 9007 Hi + + 
 
L15 Hi + - 
ATCC 43163 Hi + - 
 
L19 Hh - + 
ATCC 10211 Hi + - 
 
L21 Hi + + 
NCTC 4560 Hi + + 
 
L23 Hh - - 
NCTC 11315 Hi + + 
 
L35 Hi + + 
ATCC 49766 Hi + + 
 
L37 Hh + + 
ATCC 33390 Hh - + 
 
L43 Hh + + 
86 Hi + + 
 
L48 Hh + + 
RA Hi + + 
 
L52 Hh - - 
RD Hi + + 
 
L66 Hh + + 
MDU3 Hi + - 
 
L71 Hh - - 
BW1 Hh - + 
 
L76 Hi + + 
BW2 Hh + + 
 
L79 Hi + + 
BW15 Hh + - 
 
L93 Hh - - 
BW16 Hh + + 
 
L95 Hh + + 
BW18 Hh + + 
 
L139 Hi + + 
CF5 Hh + + 
 
L143 Hi + + 
CF14 Hh + - 
 
L146 Hi + + 
CF26 Hh + + 
 
L267 Hi + + 
CF28A Hi + + 
 
M05 Hh + + 
CF28B Hh + - 
 
M26 Hh + + 
CF31 Hi + + 
 
NF1 Hh + + 
CF34 Hi + + 
 
NF3 Hi + + 
CF48 Hi + + 
 
NF7 Hi + + 
CF53 Hh - - 
 
NF30 Hi + + 
Ci2 Hi + + 
 
NF37 Hi + + 
Ci3 Hi + + 
 
NF38 Hi + + 
Ci5 Hi + + 
 
RHH4 Hi + + 
Ci8 Hi + + 
 
RHH7 Hi + + 
Ci9 Hi + + 
 
RHH12 Hi + + 
Ci29 Hi + + 
 
RHH14 Hi + + 
Ci37 Hi + + 
 
RHH15 Hi + + 
L4 Hh + + 
 
RHH17 Hi + + 
L5 Hh - - 
 
RHH19 Hi + + 
L6 Hh - - 
 
RHH21 Hi + + 
L13 Hi + + 
 
RHH32 Hi + + 
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Strain Specie
 
BW1-
 
Haemoci
 
 
Species, strain BW1-
 
Haemoci
 RHH41
 
Hi + + 
 
S. pneum, 10582 - - 
RHH41
 
Hi + + 
 
S. pneum, 6305 - - 
RHH43 Hi + + 
 
S. pyogenes, 19615 - - 
RHH44 Hi + + 
 
S. bovis, 35034 - - 
RHH47 Hi + + 
 
E. faecalis, 29212 - - 
RHH48 Hi + + 
 
E. faecalis, POW 1995 - - 
RHH50 Hi + + 
 
E. faecicum, 99p51661 - - 
RHH51 Hi + + 
 
E. gallinarum, ATCC 49673 - - 
RHH56 Hi + + 
 
A. baumannii, ATCC … - - 
RHH58 Hh - - 
 
Burk. cepacia, ATCC 
 
- - 
RHH60 Hi + + 
 
C. albic., ATCC 10231 - - 
RHH61 Hh - - 
 
E.coli, DH5 alpha - + 
RHH62 Hi - + 
 
E.coli, NCTC 11560 - + 
RHH64 Hi + + 
 
E.coli, 10418 - + 
RHH68 Hi + + 
 
Proteus vulgaris, ATCC 
 
- - 
RHH73 Hi + + 
 
M. cat., ATCC 25238 - + 
RHH75 Hh + + 
 
N. lact., ATCC 239709 - + 
RHH80 Hi - + 
 
P. aeruginosa, PA01 - - 
RHH82 Hi + + 
 
MRSA, ATCC 33591 - - 
RHH84 Hi + + 
 
S. epid., ATCC 12228 - - 
RHH88 Hi + + 
 
S. aureus, ATCC 25923 - - 
RHH89 Hi + + 
 
S. aureus, ATCC 29213 - - 
RHH91 Hi + + 
    
RHH92 Hi + + 
    
RHH93 Hi + + 
    
RHH96 Hi + + 
    
RHH99 Hi + + 
    
RHH101 Hi + + 
    
RHH103 Hi + + 
    
RHH106 Hi + + 
    
RHH112 Hh - - 
    
RHH116 Hi + + 
    
RHH118 Hi + + 
    
RHH125 Hi + + 
    
RHH126 Hi + + 
    
RHH127 Hi + + 
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Appendix 3. 
Alignment of Hh-NIS sequences. 
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